{
  "data": [
    {
      "ingredient2": "Brinzolamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206376,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Flecainide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206377,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206378,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Zopiclone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206379,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Mitoxantrone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206381,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206383,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ceftriaxone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206384,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206385,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Finasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206386,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Anastrozole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206387,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Dantrolene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206388,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Rifaximin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206389,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206390,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Quetiapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206391,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Paclitaxel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206392,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Pemoline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206393,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Saquinavir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206394,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Metoclopramide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206395,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206396,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Sevoflurane",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206397,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Aripiprazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206398,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Gemfibrozil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206399,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206400,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Iodixanol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206401,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206402,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Posaconazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206403,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Paliperidone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206404,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Varenicline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206405,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Hydralazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206406,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Pirbuterol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206407,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206408,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Cefazolin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206409,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Vecuronium",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206410,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Sodium bicarbonate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206411,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Tiotropium",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206412,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ciclesonide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206413,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Cefepime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206414,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Cefpodoxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206415,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Acenocoumarol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206416,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ursodeoxycholic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206417,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Nitrazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206418,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Valganciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206419,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206420,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Thiothixene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206421,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Calcipotriol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206422,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Thiotepa",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206423,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ambrisentan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206424,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Desvenlafaxine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206425,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Aliskiren",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206426,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ioversol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206427,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Iopromide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206428,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Vitamin D",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206429,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Clobetasol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206430,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Fluticasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206431,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Loteprednol etabonate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206432,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Aminocaproic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208472,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Adenosine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213273,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Mannitol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216408,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Alprostadil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217576,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Cytarabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224569,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229673,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231430,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Epoprostenol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234640,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Acetylcysteine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236218,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Galactose",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236643,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Goserelin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205972,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Desmopressin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205973,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Eptifibatide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205974,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205975,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Octreotide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205976,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Cyanocobalamin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205977,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Calcitriol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205978,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Folic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205979,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Vitamin A",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205980,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Pravastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205981,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Fluvoxamine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205982,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205983,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ramipril",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205984,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Flunisolide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205985,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Baclofen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205986,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Nicotine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205987,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Lorazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205988,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205989,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Tramadol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205990,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205991,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Oseltamivir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205992,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205993,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Hydroxocobalamin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205994,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Sildenafil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205995,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205996,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Azithromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205997,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ticlopidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205998,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Adapalene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205999,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Midodrine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206000,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Torasemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206001,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206002,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Eletriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206003,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Moxifloxacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206004,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Gadodiamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206005,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Pregabalin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206006,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Temazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206007,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Nevirapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206008,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ranolazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206009,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Mesalazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206010,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ziprasidone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206011,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Cabergoline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206012,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Dapsone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206013,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Doxycycline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206014,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Clotrimazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206015,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Anagrelide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206016,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Carmustine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206017,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ropinirole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206018,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Isradipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206019,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Topiramate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206020,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Argatroban",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206021,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Liothyronine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206022,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Lidocaine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206023,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Pamidronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206024,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Venlafaxine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206025,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Travoprost",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206026,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Atomoxetine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206027,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Chlorambucil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206028,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Etomidate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206029,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Morphine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206030,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Bupivacaine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206031,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ertapenem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206032,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Mitomycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206033,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Bexarotene",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206034,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Chlorthalidone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206035,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Valproic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206036,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Zolmitriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206037,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Acetaminophen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206038,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206039,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Piperacillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206040,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Dihydroergotamine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206041,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206042,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206043,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ethambutol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206044,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Methadone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206045,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Olanzapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206046,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Pimecrolimus",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206047,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Pyrazinamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206048,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Cetirizine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206049,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206050,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Alfuzosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206051,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Minoxidil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206052,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Aztreonam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206053,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Chlorzoxazone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206054,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Vinorelbine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206055,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206056,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Mirtazapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206058,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Meprobamate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206059,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Treprostinil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206060,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Trihexyphenidyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206061,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Palonosetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206062,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Mexiletine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206063,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Amlodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206064,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Nimodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206065,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Carisoprodol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206066,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Progesterone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206067,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Zoledronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206068,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Nisoldipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206069,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206070,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Mupirocin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206071,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Pramipexole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206072,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ampicillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206073,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Phenoxymethylpenicillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206074,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206075,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Methylphenidate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206076,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Methocarbamol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206077,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206078,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Famciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206079,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Prochlorperazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206080,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Nitric Oxide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206081,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Allopurinol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206082,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Ceftazidime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206083,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Cerivastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206084,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Trimethoprim",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206085,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Gemcitabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206086,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 206087,
      "ingredient1": "Levothyroxine"
    },
    {
      "ingredient2": "Acalabrutinib",
      "severity": "Major",
      "effect": "Coadministration of acalabrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.",
      "management_text": "Concomitant use of acalabrutinib in patients receiving other medications that interfere with platelet function or coagulation should be approached with caution. Close clinical and laboratory monitoring for bleeding complications is recommended during therapy. Patients should be advised to promptly report any signs and symptoms of bleeding to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 2728,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Major",
      "effect": "The antiplatelet and cardioprotective effect of low-dose aspirin may be antagonized by coadministration of some nonsteroidal anti-inflammatory drugs (NSAIDs). Ibuprofen has been specifically implicated, and there is evidence that others including indomethacin, naproxen, and tiaprofenic acid may also interact. The mechanism is competitive inhibition of platelet cyclooxygenase by certain NSAIDs, which, unlike aspirin, bind reversibly at the active site of the enzyme and cause a temporary rather than persistent depression of thromboxane formation and thromboxane-dependent platelet function. The combined use of aspirin with NSAIDs in general may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation.",
      "management_text": "Patients receiving low-dose aspirin for cardioprotection should avoid the regular use of ibuprofen and possibly other NSAIDs. Occasional use of ibuprofen is acceptable, as the risk from any attenuation of the antiplatelet effect of low-dose aspirin is likely to be minimal given the long-lasting effect of aspirin on platelets. In patients receiving immediate-release (not enteric-coated) aspirin, single doses of ibuprofen 400 mg may be used but should not be administered within 8 hours before or 30 minutes after the aspirin dose. There are currently no specific recommendations regarding the dosing and timing of single-dose ibuprofen in patients receiving enteric-coated low-dose aspirin. For patients requiring routine NSAID therapy with concomitant low-dose aspirin, diclofenac may be a viable alternative. In the retrospective study implicating ibuprofen, 75 mg twice daily of delayed-release diclofenac did not interfere with the antiplatelet activity of aspirin. Other noninterfering alternatives for pain include acetaminophen, celecoxib, or narcotic analgesics. In any case, caution is advised whenever aspirin is combined with a NSAID due to the potential for additive GI toxicity. Patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as abdominal pain, bloating, sudden dizziness or lightheadedness, nausea, vomiting, hematemesis, anorexia, and melena.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10165,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Anisindione",
      "severity": "Major",
      "effect": "Aspirin, even in small doses, may increase the risk of bleeding in patients on oral anticoagulants by inhibiting platelet aggregation, prolonging bleeding time, and inducing gastrointestinal lesions. Analgesic/antipyretic doses of aspirin increase the risk of major bleeding more than low-dose aspirin; however bleeding has also occurred with low-dose aspirin.",
      "management_text": "This combination, especially with analgesic/antipyretic aspirin doses, should generally be avoided unless the potential benefit outweighs the risk of bleeding. If concomitant therapy is used for additive anticoagulant effects, monitoring for excessive anticoagulation and overt and occult bleeding is recommended. The INR should be checked frequently and the dosage adjusted accordingly when aspirin is added to an anticoagulant regimen. Be cognizant that bleeding may occur without INR or prothrombin time increases. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bruising, red or brown urine, or red or black stools. Patients should also be counseled to avoid any other over-the-counter oral or topical salicylate products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33776,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Brinzolamide (ophthalmic)",
      "severity": "Major",
      "effect": "The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate toxicity. The mechanism is unknown but may involve salicylate-induced displacement of CAIs from plasma protein-binding sites and reduced renal clearance, or CAI-induced plasma pH changes resulting in increased amounts of unionised salicylates entering the CNS.",
      "management_text": "In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended. If coadministration is necessary, careful monitoring of the patient's mental status and acid base balance is strongly recommended. Patients should be advised to promptly notify their physicians if they experience symptoms such as lethargy, tinnitus, confusion, nausea, vomiting, or hyperventilation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33791,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dalteparin",
      "severity": "Major",
      "effect": "In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH) or heparinoid therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs). The development of epidural and spinal hematoma can lead to long-term or permanent paralysis. Theoretically, NSAIDs may potentiate the risk of bleeding complications associated with LMWH or heparinoid therapy. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals. While these effects are generally slight and of relatively short duration with most NSAIDs (except aspirin) at recommended dosages, they may be of pronounced clinical significance when combined with the inhibitory effects of LMWHs or heparinoids on the clotting cascade.",
      "management_text": "Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33819,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Defibrotide",
      "severity": "Major",
      "effect": "Coadministration of defibrotide with antiplatelet agents or other agents that affect coagulation may increase the risk of bleeding. In vitro, defibrotide increased the activity of fibrinolytic enzymes. In a mouse model of thromboembolism, recombinant tissue plasminogen activator (t-PA) potentiated the antithrombotic effect of defibrotide when given intravenously.",
      "management_text": "Concomitant use of medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with defibrotide. Close clinical and laboratory observation for bleeding complications is recommended during therapy. If bleeding develops, defibrotide should be discontinued and treatment/supportive care provided until the bleeding stops.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33823,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Desirudin",
      "severity": "Major",
      "effect": "Coadministration of thrombin inhibitors with drugs that affect platelet function may potentiate the risk of bleeding due to additive or synergistic effects on hemostasis. In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during thrombin inhibitor therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs) and platelet inhibitors.",
      "management_text": "Close clinical and laboratory observation for bleeding complications is recommended if thrombin inhibitors are used with drugs that interfere with platelet function, including long-term or chronic NSAIDs. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with extreme caution and only after thorough assessment of risks and benefits. Besides bleeding complications, these patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction. Urgent diagnosis and treatment (e.g., spinal cord decompression) are required if signs or symptoms of spinal hematoma develop.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33827,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Diclofenamide",
      "severity": "Major",
      "effect": "The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate toxicity. The mechanism is unknown but may involve salicylate-induced displacement of CAIs from plasma protein-binding sites and reduced renal clearance, or CAI-induced plasma pH changes resulting in increased amounts of unionised salicylates entering the CNS.",
      "management_text": "In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended. If coadministration is necessary, careful monitoring of the patient's mental status and acid base balance is strongly recommended. Patients should be advised to promptly notify their physicians if they experience symptoms such as lethargy, tinnitus, confusion, nausea, vomiting, or hyperventilation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33833,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cabozantinib",
      "severity": "Major",
      "effect": "Coadministration of cabozantinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with cabozantinib is associated with severe, sometimes fatal hemorrhage including hemoptysis and gastrointestinal hemorrhage.",
      "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with cabozantinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 34073,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Caplacizumab",
      "severity": "Major",
      "effect": "Concomitant use of caplacizumab with other agents that affect hemostasis such as anticoagulants, platelet aggregation inhibitors, thrombolytic agents, or drugs that cause thrombocytopenia may increase the risk of bleeding.",
      "management_text": "Caution is recommended if caplacizumab must be used with other agents that affect hemostasis. Patients should be monitored for potential bleeding complications and therapy interrupted if clinically significant bleeding occurs. If needed, von Willebrand factor concentrate may be administered to rapidly correct hemostasis.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 34075,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Danaparoid",
      "severity": "Major",
      "effect": "In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH) or heparinoid therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs). The development of epidural and spinal hematoma can lead to long-term or permanent paralysis. Theoretically, NSAIDs may potentiate the risk of bleeding complications associated with LMWH or heparinoid therapy. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals. While these effects are generally slight and of relatively short duration with most NSAIDs (except aspirin) at recommended dosages, they may be of pronounced clinical significance when combined with the inhibitory effects of LMWHs or heparinoids on the clotting cascade.",
      "management_text": "Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 34099,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Deferasirox",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of gastrointestinal bleeding associated with the use of deferasirox. Theoretical concerns exist regarding the potential for increased risk of renal impairment during coadministration of deferasirox with other nephrotoxic agents, including NSAIDs when used chronically or in high dosages.",
      "management_text": "Caution is advised if deferasirox is used in combination with NSAIDs. Patients should be advised to contact their physician if they develop potential signs and symptoms of gastrointestinal injury such as abdominal pain, bloating, dizziness, lightheadedness, vomiting blood, anorexia, or black, tarry stools. Serum creatinine and/or creatinine clearance should be closely monitored (e.g., prior to initiation of deferasirox therapy, then weekly during the first month after initiation or modification of therapy and monthly thereafter), especially in the elderly and patients with preexisting renal impairment, comorbid conditions, dehydration, or severe infections. Dosage reduction, interruption, or discontinuation should be considered in the presence of creatinine elevations. A progressive increase in serum creatinine beyond the age-appropriate upper limit of normal may warrant an interruption of therapy. Once the creatinine has returned to within the normal range, therapy may be reinitiated at a lower dose followed by a gradual dose escalation according to the product labeling, provided the clinical benefit is expected to outweigh potential risks.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 34101,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Edoxaban",
      "severity": "Major",
      "effect": "Concomitant use of edoxaban with other agents that alter hemostasis such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), platelet aggregation inhibitors, other anticoagulants, thrombolytic agents, or drugs that cause thrombocytopenia may increase the risk of bleeding.",
      "management_text": "Caution is recommended if edoxaban must be used with other agents that alter hemostasis. Patients should be monitored for increased anticoagulant effects and bleeding complications. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 34108,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Enoxaparin",
      "severity": "Major",
      "effect": "In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during low molecular weight heparin (LMWH) or heparinoid therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs). The development of epidural and spinal hematoma can lead to long-term or permanent paralysis. Theoretically, NSAIDs may potentiate the risk of bleeding complications associated with LMWH or heparinoid therapy. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals. While these effects are generally slight and of relatively short duration with most NSAIDs (except aspirin) at recommended dosages, they may be of pronounced clinical significance when combined with the inhibitory effects of LMWHs or heparinoids on the clotting cascade.",
      "management_text": "Products containing NSAIDs, especially if given chronically and in high dosages, should preferably be avoided in patients receiving LMWHs or heparinoids. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 34109,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ibrutinib",
      "severity": "Major",
      "effect": "Coadministration of ibrutinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.",
      "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with ibrutinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. The INR should be monitored more frequently during coadministration of warfarin.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 34138,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Inotersen",
      "severity": "Major",
      "effect": "Coadministration of inotersen and drugs that interfere with platelet function or coagulation may potentiate the risk of serious, potentially life-threatening bleeding complications, including spontaneous intracranial and intrapulmonary hemorrhage. Inotersen causes reductions in platelet count that may result in sudden and unpredictable thrombocytopenia.",
      "management_text": "Caution is advised when inotersen is prescribed with antiplatelet agents, anticoagulants, or other medications that commonly cause thrombocytopenia or bleeding. A platelet count should be obtained prior to initiation of inotersen and regularly during and for at least 8 weeks after treatment in accordance with the product labeling. Inotersen should not be administered in patients with a platelet count below 100 x 10^9/L or in patients who are unable to adhere to the recommended laboratory monitoring and management guidelines. Patients or their caregivers should be apprised of the signs and symptoms of thrombocytopenia and to seek medical attention if they occur, including any unusual or prolonged bleeding (e.g., petechiae, easy bruising, hematoma, subconjunctival bleeding, gingival bleeding, epistaxis, hemoptysis, irregular or heavier than normal menstrual bleeding, hematemesis, hematuria, hematochezia, melena), neck stiffness, or atypical severe headache.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 34142,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Major",
      "effect": "Coadministration of dasatinib and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications. Treatment with dasatinib is associated with severe thrombocytopenia.",
      "management_text": "Concomitant use of other medications that interfere with platelet function or coagulation should be considered cautiously in patients treated with dasatinib. Close clinical and laboratory observation for bleeding complications is recommended during therapy. A complete blood count (CBC) with differential and platelet count should be obtained prior to and at least weekly for the first 2 months, then monthly thereafter or as clinically indicated. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 52022,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ibritumomab tiuxetan",
      "severity": "Major",
      "effect": "Coadministration of radiolabeled ibritumomab tiuxetan and drugs that interfere with platelet function or coagulation may potentiate the risk of bleeding complications.",
      "management_text": "Caution is advised if radiolabeled ibritumomab tiuxetan is used in combination with drugs that interfere with platelet function or coagulation.  Close clinical and laboratory observation for bleeding complications is recommended during and after treatment.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 289562,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fondaparinux",
      "severity": "Major",
      "effect": "In patients receiving neuraxial anesthesia or spinal puncture, the risk of developing an epidural or spinal hematoma during LMWH, heparinoid, or fondaparinux therapy may be increased by the concomitant use of other drugs that affect coagulation, including nonsteroidal anti-inflammatory drugs (NSAIDs). The development of epidural and spinal hematoma can lead to long-term or permanent paralysis. Theoretically, NSAIDs may potentiate the risk of bleeding complications associated with the use of fondaparinux. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals.",
      "management_text": "Products containing NSAIDs, especially if given chronically or in high dosages, should preferably be discontinued prior to initiation of fondaparinux therapy. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary. In patients undergoing neuraxial intervention, coadministration of these agents should be approached with caution and only after thorough assessment of risks and benefits. Besides bleeding complications, patients should also be monitored frequently for signs and symptoms of neurologic impairment such as midline back pain, sensory and motor deficits (numbness or weakness in lower limbs), and bowel or bladder dysfunction.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 14730,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dicoumarol",
      "severity": "Major",
      "effect": "Aspirin, even in small doses, may increase the risk of bleeding in patients on oral anticoagulants by inhibiting platelet aggregation, prolonging bleeding time, and inducing gastrointestinal lesions. Analgesic/antipyretic doses of aspirin increase the risk of major bleeding more than low-dose aspirin; however bleeding has also occurred with low-dose aspirin.",
      "management_text": "This combination, especially with analgesic/antipyretic aspirin doses, should generally be avoided unless the potential benefit outweighs the risk of bleeding. If concomitant therapy is used for additive anticoagulant effects, monitoring for excessive anticoagulation and overt and occult bleeding is recommended. The INR should be checked frequently and the dosage adjusted accordingly when aspirin is added to an anticoagulant regimen. Be cognizant that bleeding may occur without INR or prothrombin time increases. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bruising, red or brown urine, or red or black stools. Patients should also be counseled to avoid any other over-the-counter oral or topical salicylate products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33836,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dorzolamide (ophthalmic)",
      "severity": "Major",
      "effect": "The combination of large doses of salicylates and oral carbonic anhydrase inhibitors (CAI) may rarely result in severe metabolic acidosis and/or salicylate toxicity. The mechanism is unknown but may involve salicylate-induced displacement of CAIs from plasma protein-binding sites and reduced renal clearance, or CAI-induced plasma pH changes resulting in increased amounts of unionised salicylates entering the CNS.",
      "management_text": "In general, concomitant use of antirheumatic doses of salicylates and oral CAIs is not recommended. If coadministration is necessary, careful monitoring of the patient's mental status and acid base balance is strongly recommended. Patients should be advised to promptly notify their physicians if they experience symptoms such as lethargy, tinnitus, confusion, nausea, vomiting, or hyperventilation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33843,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Drotrecogin alfa",
      "severity": "Major",
      "effect": "Coadministration of drotrecogin alfa and other drugs that interfere with coagulation or platelet function may potentiate the risk of bleeding complications. Drotrecogin alfa inactivates blood clotting factors Va and VIIIa and may prolong the activated partial thromboplastin time (APTT). Treatment with drotrecogin alfa alone has been associated with serious and life-threatening bleeding episodes, including gastrointestinal, intracranial and retroperitoneal hemorrhage, although most severely ill septic patients are already at a high risk of bleeding because of coagulopathies associated with prolonged APTT and prothrombin time (PT).",
      "management_text": "The potentially increased risk of bleeding versus the benefits of drotrecogin alfa therapy should be carefully considered in seriously ill septic patients who have recently (within 7 days) received oral anticoagulants, platelet inhibitors, or aspirin (more than 650 mg/day). Close clinical and laboratory monitoring for bleeding complications is recommended if concurrent therapy is required. Drotrecogin alfa should be discontinued immediately if clinically significant bleeding occurs. Continued use of other agents that may have contributed to the bleeding should be carefully assessed. Once adequate hemostasis is attained, drotrecogin alfa may be resumed if necessary.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33847,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Gemifloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15900,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Aliskiren",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of aliskiren. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Clinical data are limited. Concomitant use of NSAIDs and aliskiren may cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function. Acute renal failure may occur, although effects are usually reversible.",
      "management_text": "Patients receiving aliskiren who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 16756,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Aluminum hydroxide",
      "severity": "Moderate",
      "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance.",
      "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33773,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Bromfenac",
      "severity": "Moderate",
      "effect": "The combined use of low-dose or high-dose aspirin with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation. Aspirin at anti-inflammatory dosages or higher may also decrease the plasma concentrations of many NSAIDs. The decreases have ranged from none or small (piroxicam, meloxicam, naproxen, tolmetin) to substantial (flurbiprofen, ibuprofen). However, the therapeutic response does not appear to be affected.",
      "management_text": "Caution is advised if aspirin, particularly at anti-inflammatory dosages, is used with other NSAIDs. Concomitant administration of NSAIDs is considered contraindicated or not recommended with aspirin at analgesic/anti-inflammatory dosages by many NSAID manufacturers. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as abdominal pain, bloating, sudden dizziness or lightheadedness, nausea, vomiting, hematemesis, anorexia, and melena.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33792,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Moderate",
      "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity. Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.",
      "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs. Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33794,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Calcium carbonate",
      "severity": "Moderate",
      "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance.",
      "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33798,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Moderate",
      "effect": "Some investigators suggest that coadministration with aspirin may attenuate the vasodilator and hypotensive effects of ACE inhibitors. In addition, some have found that the benefits of ACE inhibitors on morbidity and mortality in post-acute myocardial infarction, coronary heart disease, and particularly congestive heart failure may be compromised or even nullified by aspirin. The proposed mechanism is aspirin inhibition of cyclooxygenase, resulting in suppression of prostaglandin synthesis and prostaglandin-mediated hemodynamic effects of ACE inhibitors. However, evidence of a negative interaction is largely contradictory, and interpretation of relevant data has often been complicated by multiple confounding elements as well as the retrospective or post hoc nature of most studies.",
      "management_text": "Based on current data, it is difficult to determine the likelihood of a negative interaction between aspirin and ACE inhibitors and its clinical relevance during long-term therapy, particularly in congestive heart failure. Current recommendations generally do not preclude combination use in patients with cardiovascular diseases or risk factors that might otherwise benefit from the drugs independently. However, patients receiving long-term therapy with the combination should undergo regular blood pressure and other appropriate clinical monitoring such as renal function assessments. The lowest therapeutic dosage of aspirin should be used.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33802,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Activated charcoal",
      "severity": "Moderate",
      "effect": "Charcoal may reduce the absorption of many drugs and can absorb enterohepatically circulated drugs. Clinical utility may be the reduction either of the effects or of the toxicity of many drugs. Activated charcoal may adsorb any therapeutic agents administered while it is in the gastrointestinal tract.",
      "management_text": "The regular ingestion of charcoal should be avoided by patients requiring maintenance medications. If concomitant use is necessary, the dosage or route of administration may need to be altered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33806,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Clomipramine",
      "severity": "Moderate",
      "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.",
      "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33814,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Deflazacort",
      "severity": "Moderate",
      "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity. Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.",
      "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs. Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33824,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Delafloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33825,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Deoxycholic acid",
      "severity": "Moderate",
      "effect": "Coadministration with agents that alter hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytics, or agents that commonly cause thrombocytopenia may increase the risk of submental hematoma or bruising in association with deoxycholic acid administration.",
      "management_text": "Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33826,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Desvenlafaxine",
      "severity": "Moderate",
      "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.",
      "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33829,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Moderate",
      "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity. Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.",
      "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs. Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33830,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Drospirenone",
      "severity": "Moderate",
      "effect": "The use of drospirenone may potentiate the risk of hyperkalemia in patients receiving chronic treatment with drugs that can increase serum potassium such as angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, potassium-sparing diuretics, aldosterone antagonists, nonsteroidal anti-inflammatory drugs (NSAIDs), potassium preparations, and miscellaneous agents like cyclosporine, heparin, tacrolimus, and trimethoprim. Drospirenone has antimineralocorticoid activity and may induce hyperkalemia in susceptible patients.",
      "management_text": "Serum potassium levels should be checked regularly during concomitant therapy with drospirenone and other agents that can increase serum potassium. Particular caution is warranted in patients with renal impairment, diabetes, old age, severe or worsening heart failure, or dehydration. Patients should be advised to seek medical attention if they experience signs and symptoms of hyperkalemia such as nausea, vomiting, weakness, listlessness, tingling of the extremities, paralysis, confusion, weak pulse, and a slow or irregular heartbeat.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33846,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Epoprostenol",
      "severity": "Moderate",
      "effect": "Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.",
      "management_text": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33855,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Moderate",
      "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.",
      "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33858,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Etidronic acid",
      "severity": "Moderate",
      "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.",
      "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33862,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Felodipine",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33864,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Gatifloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33873,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33879,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33880,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Moderate",
      "effect": "Theoretically, the coadministration of nonsteroidal anti-inflammatory drugs (NSAIDs) and heparin or low molecular weight heparin (LMWH) may potentiate the risk of bleeding. NSAIDs interfere with platelet adhesion and aggregation and may prolong bleeding time in healthy individuals. In addition, NSAIDs are known to cause dose-related gastrointestinal bleeding, which may be complicated by anticoagulant therapy.",
      "management_text": "Until further data are available, products containing NSAIDs, especially if given chronically or in high dosages, should preferably be avoided in patients receiving heparin or LMWH. Close clinical and laboratory observation for bleeding complications is recommended if concurrent therapy is necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33884,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Hydralazine",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of hydralazine and dihydralazine. This interaction suggests that prostaglandins play a pivotal role in the vasodilatory effects of hydralazine.",
      "management_text": "Recommended management consists of monitoring the antihypertensive effectiveness of hydralazine or dihydralazine during therapy, increasing the dosage as necessary, or decreasing or substituting another drug for the NSAID.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33886,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Insulin aspart (aspart)",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33896,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Insulin degludec",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33898,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Insulin detemir",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33899,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Insulin glulisine",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33901,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and angiotensin II receptor antagonists may cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function.",
      "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33910,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Iodide I-123",
      "severity": "Moderate",
      "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.",
      "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34009,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Iodide I-131",
      "severity": "Moderate",
      "effect": "INTERVAL: Certain drugs may affect the pharmacokinetics, pharmacodynamics, and/or diagnostic results of radioiodides.",
      "management_text": "Antithyroid agents such as carbimazole or propylthiouracil should generally be withheld for 1 week before administration of sodium iodide I-131 or I-123, and for a few days afterward. Salicylates, steroids, anticoagulants, antihistamines, antiparasitics, penicillins, sulfonamides, tolbutamide, thiopental, and nitroprusside should generally be withheld for 1 week. Amiodarone, lithium, and benzodiazepines should be withheld for at least 4 weeks.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34010,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Calaspargase pegol",
      "severity": "Moderate",
      "effect": "Asparaginase therapy may lead to imbalances in coagulation factors predisposing the patient to bleeding or thrombosis. Theoretically, concurrent use of anticoagulants and asparaginase may increase the risk of bleeding. Hemorrhages grade 3 and above and CNS hemorrhages have been observed with asparaginase treatment.",
      "management_text": "Coagulation parameters should be monitored at baseline and periodically during concomitant treatment with asparaginase and anticoagulants such as heparin, dipyridamole, aspirin and nonsteroidal anti-inflammatory drugs. Patients should be advised to promptly report any signs and symptoms of bleeding.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34074,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dexfenfluramine",
      "severity": "Moderate",
      "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.",
      "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34103,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Garlic",
      "severity": "Moderate",
      "effect": "Garlic may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Garlic has been shown in some studies to have antithrombotic effects and may increase fibrinolysis, decrease platelet aggregation, and increase prothrombin time. Antiplatelet activity is present in garlic powder, aged garlic preparations, garlic oil, and fresh garlic (more so raw than when it is cooked). There have been isolated reports of bleeding complications associated with chronic, high dietary intake of garlic, as well as reports suggesting an interaction between warfarin and garlic resulting in increased INR.",
      "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of garlic supplements and large amounts of garlic should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34130,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ginger",
      "severity": "Moderate",
      "effect": "Ginger may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. Limited data suggest that ginger may decrease platelet aggregation via the inhibition of thromboxane synthetase, although some studies have found no effect on platelet function or thromboxane production or activity.",
      "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used ginger and ginger supplements extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34132,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ginkgo biloba",
      "severity": "Moderate",
      "effect": "Ginkgo may potentiate the risk of bleeding associated with anticoagulants, platelet inhibitors, and thrombolytic agents. Ginkgolide B, a component of ginkgo, inhibits platelet-activating factor by displacing it from its receptor-binding site, resulting in reduced platelet aggregation.",
      "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of ginkgo should be avoided during use of coagulation-modifying agents and at least two weeks prior to surgery. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34133,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ginseng",
      "severity": "Moderate",
      "effect": "Ginseng may potentiate the effects of anticoagulants, platelet inhibitors and thrombolytic agents, possibly increasing the risk of bleeding. In vitro studies have shown that one or more of the active constituents of ginseng, known as ginsenosides, can decrease platelet aggregation, although it is not known whether these constituents are absorbed or are bioactive in humans. Bleeding complications secondary to antiplatelet activity have not been reported.",
      "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In general, consumption of ginseng supplements and large amounts of ginseng should preferably be avoided during use of coagulation-modifying agents. In patients who have used this herb extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34134,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Hemin",
      "severity": "Moderate",
      "effect": "Theoretically, hemin may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. Hemin has exhibited mild, transient anticoagulant effects during clinical studies.",
      "management_text": "The use of hemin with concurrent anticoagulant therapy should be avoided. Caution is advised if hemin is used in combination with other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34136,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Iloprost",
      "severity": "Moderate",
      "effect": "Prostacyclin/prostacyclin analogs (e.g., epoprostenol, iloprost, treprostinil) inhibit platelet aggregation and may theoretically potentiate the risk of bleeding in patients treated with other agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia.",
      "management_text": "Caution is advised if prostacyclin and prostacyclin analogs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hemorrhagic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34139,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cilostazol",
      "severity": "Moderate",
      "effect": "Coadministration of cilostazol with other antiplatelet agents may produce additive pharmacodynamic effects resulting in increased inhibition of platelet function.",
      "management_text": "Because of theoretical concerns regarding increased inhibition of platelet aggregation, cilostazol should be used cautiously with other antiplatelet agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 52008,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Bismuth subsalicylate",
      "severity": "Moderate",
      "effect": "Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding, ulceration) and bruising or bleeding.",
      "management_text": "Concomitant use of more than one salicylate at a time should generally be avoided.  Patients treated with a salicylate should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 253445,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Choline salicylate",
      "severity": "Moderate",
      "effect": "Concomitant use of more than one salicylate at a time may increase the potential for gastrointestinal adverse effects (e.g., inflammation, pain, bleeding, ulceration) and bruising or bleeding.",
      "management_text": "Concomitant use of more than one salicylate at a time should generally be avoided.  Patients treated with a salicylate should be advised to take it with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 253447,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Diroximel fumarate",
      "severity": "Moderate",
      "effect": "The use of fumaric acid esters in combination with medications that can cause nephrotoxicity, including aspirin at anti-inflammatory dosages, may increase the potential for adverse renal reactions.",
      "management_text": "Administration of non-enteric coated aspirin (up to 325 mg) prior to fumaric acid esters such as monomethyl fumarate or its prodrugs, dimethyl fumarate or diroximel fumarate, may help reduce the incidence and/or severity of flushing.  However, as there are no long-term studies evaluating the continuous use of aspirin in this situation for longer than 4 weeks, caution is advised.  Assessment of renal function (e.g., serum creatinine, blood urea nitrogen, urinalysis) is recommended prior to initiating treatment with fumaric acid esters and as clinically indicated during treatment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 289561,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Abciximab",
      "severity": "Moderate",
      "effect": "Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due to the additive inhibitory effects of salicylates on platelet function.",
      "management_text": "It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications. Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites. Therapy should be discontinued immediately if serious or uncontrollable bleeding or thrombocytopenia occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 964,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Moderate",
      "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity. Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.",
      "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs. Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11078,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.",
      "management_text": "Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12434,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Alendronic acid",
      "severity": "Moderate",
      "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.",
      "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13948,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fluvoxamine",
      "severity": "Moderate",
      "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.",
      "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 14609,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fosinopril",
      "severity": "Moderate",
      "effect": "Some investigators suggest that coadministration with aspirin may attenuate the vasodilator and hypotensive effects of ACE inhibitors. In addition, some have found that the benefits of ACE inhibitors on morbidity and mortality in post-acute myocardial infarction, coronary heart disease, and particularly congestive heart failure may be compromised or even nullified by aspirin. The proposed mechanism is aspirin inhibition of cyclooxygenase, resulting in suppression of prostaglandin synthesis and prostaglandin-mediated hemodynamic effects of ACE inhibitors. However, evidence of a negative interaction is largely contradictory, and interpretation of relevant data has often been complicated by multiple confounding elements as well as the retrospective or post hoc nature of most studies.",
      "management_text": "Based on current data, it is difficult to determine the likelihood of a negative interaction between aspirin and ACE inhibitors and its clinical relevance during long-term therapy, particularly in congestive heart failure. Current recommendations generally do not preclude combination use in patients with cardiovascular diseases or risk factors that might otherwise benefit from the drugs independently. However, patients receiving long-term therapy with the combination should undergo regular blood pressure and other appropriate clinical monitoring such as renal function assessments. The lowest therapeutic dosage of aspirin should be used.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 15040,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Alteplase",
      "severity": "Moderate",
      "effect": "Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.",
      "management_text": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin. Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 19606,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Diclofenac (topical)",
      "severity": "Moderate",
      "effect": "Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.",
      "management_text": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20112,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Amikacin",
      "severity": "Moderate",
      "effect": "The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods. Animal models suggest that renal prostaglandins may play a role in maintaining normal renal blood flow and glomerular filtration rate during the development of aminoglycoside nephrotoxicity, thus inhibition of their production by NSAIDs may worsen the renal damage. In premature infants, NSAIDs may increase the plasma concentrations of aminoglycosides. The proposed mechanism is decreased aminoglycoside clearance due to NSAID reduction of glomerular filtration rate.",
      "management_text": "Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy. If concomitant administration is necessary, hydration status as well as renal and vestibular functions should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20773,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Amlodipine",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 22823,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Anagrelide",
      "severity": "Moderate",
      "effect": "Anagrelide and aspirin may potentiate each other's antiplatelet effects when they are coadministered.",
      "management_text": "Before initiation of combination treatment, the risks and benefits should be assessed, especially in patients who have a high risk for hemorrhage and/or whose platelet counts are greater than 1000 x 10(9)/L.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24675,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Anistreplase",
      "severity": "Moderate",
      "effect": "Drugs that inhibit platelet function may increase the risk of bleeding when administered prior to, during, or after thrombolytic therapy.",
      "management_text": "Careful monitoring for signs of bleeding, particularly at arterial puncture wounds, is recommended when thrombolytics are used concurrently or sequentially with antiplatelet agents other than aspirin. Some authorities recommend avoiding the initiation of platelet aggregation inhibitors within the first 24 hours following thrombolysis treatment.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33777,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Chlorpropamide",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33807,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cinoxacin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33810,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33811,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Moderate",
      "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.",
      "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33812,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Clopidogrel",
      "severity": "Moderate",
      "effect": "Clopidogrel has been shown to potentiate the inhibition of platelet aggregation due to aspirin. The safety of chronic administration of aspirin or other salicylates with clopidogrel has not been established.",
      "management_text": "Until further data are available, caution is recommended, especially in patients at risk of bleeding (i.e., GI ulceration), if clopidogrel is coadministered on a long-term basis with drugs that may cause GI lesions. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, red or black stools, or bloody or coffee-ground emesis. Patients should also be counseled to avoid any other over-the-counter salicylate products.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33815,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Collagenase clostridium histolyticum",
      "severity": "Moderate",
      "effect": "The safety and efficacy of collagenase clostridium histolyticum in patients currently receiving, or within 7 days of receiving, anticoagulant medications other than low-dose aspirin (e.g., up to 150 mg/day) is unknown. Theoretically, the risk of bleeding complications may be increased.",
      "management_text": "Collagenase clostridium histolyticum should be used with caution in patients receiving or within 7 days of receiving anticoagulants (except for low-dose aspirin), platelet inhibitors, or thrombolytic agents.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33817,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the nephrotoxic effects of cyclosporine, especially if dehydration is present. The exact mechanism is unknown but is apparently unrelated to plasma cyclosporine levels. The interaction has been reported with diclofenac and sulindac.",
      "management_text": "Renal function should be closely monitored in patients receiving concomitant therapy with cyclosporine and NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33818,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Didanosine",
      "severity": "Moderate",
      "effect": "Chronic administration of antacids may reduce serum salicylate concentrations in patients receiving large doses of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to urinary alkalinization by antacids, resulting in increased renal salicylate clearance.",
      "management_text": "Patients treated chronically with antacids (or oral medications that contain antacids such as didanosine buffered tablets or pediatric oral solution) and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33837,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Diflunisal",
      "severity": "Moderate",
      "effect": "The combined use of low-dose or high-dose aspirin with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation. Aspirin at anti-inflammatory dosages or higher may also decrease the plasma concentrations of many NSAIDs. The decreases have ranged from none or small (piroxicam, meloxicam, naproxen, tolmetin) to substantial (flurbiprofen, ibuprofen). However, the therapeutic response does not appear to be affected.",
      "management_text": "Caution is advised if aspirin, particularly at anti-inflammatory dosages, is used with other NSAIDs. Concomitant administration of NSAIDs is considered contraindicated or not recommended with aspirin at analgesic/anti-inflammatory dosages by many NSAID manufacturers. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as abdominal pain, bloating, sudden dizziness or lightheadedness, nausea, vomiting, hematemesis, anorexia, and melena.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33838,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Digoxin",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may increase plasma digoxin concentrations and half-life. The exact mechanism is unknown, but may be related to reduced renal clearance of digoxin. The interaction has been reported with indomethacin and ibuprofen, but data for other NSAIDs are not available.",
      "management_text": "Patients who require concomitant therapy should be monitored for altered pharmacologic effects of digoxin and for increased plasma levels. The digoxin dosage may require adjustment. Patients should be advised to notify their physician if they experience nausea, anorexia, visual changes, slow pulse, or irregular heartbeats.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33839,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Moderate",
      "effect": "Several case reports have suggested that verapamil and aspirin may have synergistic antiplatelet effects. The mechanism of this interaction has not been fully elucidated. Also, one study of five patients has suggested that aspirin may reverse the antihypertensive effect of verapamil. The mechanism may be related to antagonism of the effect of verapamil on prostacyclin. Diltiazem has been shown to interact with aspirin in a similar manner.",
      "management_text": "Close observation for prolonged bleeding time and reduced antihypertensive effect is recommended if these drugs must be used together. Patients should be advised to notify their physician if they experience unusual bleeding, bruising, or petechiae. Aspirin should be discontinued if an interaction is suspected.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33840,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Moderate",
      "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.",
      "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33848,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Moderate",
      "effect": "Some investigators suggest that coadministration with aspirin may attenuate the vasodilator and hypotensive effects of ACE inhibitors. In addition, some have found that the benefits of ACE inhibitors on morbidity and mortality in post-acute myocardial infarction, coronary heart disease, and particularly congestive heart failure may be compromised or even nullified by aspirin. The proposed mechanism is aspirin inhibition of cyclooxygenase, resulting in suppression of prostaglandin synthesis and prostaglandin-mediated hemodynamic effects of ACE inhibitors. However, evidence of a negative interaction is largely contradictory, and interpretation of relevant data has often been complicated by multiple confounding elements as well as the retrospective or post hoc nature of most studies.",
      "management_text": "Based on current data, it is difficult to determine the likelihood of a negative interaction between aspirin and ACE inhibitors and its clinical relevance during long-term therapy, particularly in congestive heart failure. Current recommendations generally do not preclude combination use in patients with cardiovascular diseases or risk factors that might otherwise benefit from the drugs independently. However, patients receiving long-term therapy with the combination should undergo regular blood pressure and other appropriate clinical monitoring such as renal function assessments. The lowest therapeutic dosage of aspirin should be used.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33851,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Enoxacin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33852,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Eplerenone",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effect of eplerenone. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. In patients with renal impairment receiving these antihypertensive agents, concomitant use of NSAIDs has also resulted in severe hyperkalemia.",
      "management_text": "Patients receiving eplerenone who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33854,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Eprosartan",
      "severity": "Moderate",
      "effect": "Nonsteroidal anti-inflammatory drugs (NSAIDs) may attenuate the antihypertensive effects of angiotensin II receptor antagonists. The proposed mechanism is NSAID-induced inhibition of renal prostaglandin synthesis, which results in unopposed pressor activity producing hypertension. In addition, NSAIDs can cause fluid retention, which also affects blood pressure. Concomitant use of NSAIDs and angiotensin II receptor antagonists may cause deterioration in renal function, particularly in patients who are elderly or volume-depleted (including those on diuretic therapy) or have compromised renal function.",
      "management_text": "Patients receiving angiotensin II receptor antagonists who require prolonged (greater than 1 week) concomitant therapy with an NSAID should have blood pressure monitored more closely following initiation, discontinuation, or change of dosage of the NSAID. Renal function should also be evaluated periodically during prolonged coadministration. The interaction is not expected to occur with low doses (e.g., low-dose aspirin) or intermittent short-term administration of NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33856,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Moderate",
      "effect": "The combined use of low-dose or high-dose aspirin with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation. Aspirin at anti-inflammatory dosages or higher may also decrease the plasma concentrations of many NSAIDs. The decreases have ranged from none or small (piroxicam, meloxicam, naproxen, tolmetin) to substantial (flurbiprofen, ibuprofen). However, the therapeutic response does not appear to be affected.",
      "management_text": "Caution is advised if aspirin, particularly at anti-inflammatory dosages, is used with other NSAIDs. Concomitant administration of NSAIDs is considered contraindicated or not recommended with aspirin at analgesic/anti-inflammatory dosages by many NSAID manufacturers. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as abdominal pain, bloating, sudden dizziness or lightheadedness, nausea, vomiting, hematemesis, anorexia, and melena.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33863,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fenfluramine",
      "severity": "Moderate",
      "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.",
      "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33865,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fenoprofen",
      "severity": "Moderate",
      "effect": "The combined use of low-dose or high-dose aspirin with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation. Aspirin at anti-inflammatory dosages or higher may also decrease the plasma concentrations of many NSAIDs. The decreases have ranged from none or small (piroxicam, meloxicam, naproxen, tolmetin) to substantial (flurbiprofen, ibuprofen). However, the therapeutic response does not appear to be affected.",
      "management_text": "Caution is advised if aspirin, particularly at anti-inflammatory dosages, is used with other NSAIDs. Concomitant administration of NSAIDs is considered contraindicated or not recommended with aspirin at analgesic/anti-inflammatory dosages by many NSAID manufacturers. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as abdominal pain, bloating, sudden dizziness or lightheadedness, nausea, vomiting, hematemesis, anorexia, and melena.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33866,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fludrocortisone",
      "severity": "Moderate",
      "effect": "Coadministration with corticosteroids may decrease the serum concentrations and therapeutic effects of salicylates. Likewise, serum salicylate levels may increase following withdrawal of corticosteroid therapy, potentially resulting in salicylate toxicity. Pharmacologically, the potential for increased gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration and perforation, should be considered due to additive ulcerogenic effects of these agents (especially aspirin) on the GI mucosa.",
      "management_text": "Patients treated concomitantly with a corticosteroid may require higher dosages of salicylates or salicylate-like drugs. Pharmacologic response to these agents should be monitored more closely whenever a corticosteroid is added to or withdrawn from therapy in patients stabilized on their existing salicylate regimen, and the salicylate dosage adjusted as necessary. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as severe abdominal pain, dizziness, lightheadedness, and the appearance of black, tarry stools. The selective use of prophylactic anti-ulcer therapy (e.g., antacids, H2-antagonists) may be appropriate, particularly in patients with a prior history of peptic ulcer disease or GI bleeding and in elderly and debilitated patients.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33868,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Moderate",
      "effect": "Serotonin reuptake inhibitors (SRIs) may potentiate the risk of bleeding in patients treated with ulcerogenic agents and agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The tricyclic antidepressant, clomipramine, is also a strong SRI and may interact similarly. Serotonin release by platelets plays an important role in hemostasis, thus SRIs may alter platelet function and induce bleeding.",
      "management_text": "Caution is advised if SRIs or clomipramine are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33869,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Flurbiprofen (ophthalmic)",
      "severity": "Moderate",
      "effect": "Systemically and topically administered nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of bleeding in patients treated with anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. The pharmacologic effects of NSAIDs that contribute to this interaction include prolongation of prothrombin time and inhibition of platelet adhesion and aggregation.",
      "management_text": "Caution is advised if NSAIDs are used in combination with other drugs that affect hemostasis. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their doctor, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33871,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Gentamicin",
      "severity": "Moderate",
      "effect": "The nephrotoxic effect of aminoglycosides may be potentiated by nonsteroidal anti-inflammatory drugs (NSAIDs), particularly if the latter had been given in high dosages for prolonged periods. Animal models suggest that renal prostaglandins may play a role in maintaining normal renal blood flow and glomerular filtration rate during the development of aminoglycoside nephrotoxicity, thus inhibition of their production by NSAIDs may worsen the renal damage. In premature infants, NSAIDs may increase the plasma concentrations of aminoglycosides. The proposed mechanism is decreased aminoglycoside clearance due to NSAID reduction of glomerular filtration rate.",
      "management_text": "Whenever feasible, NSAID use should preferably be discontinued prior to initiating IV aminoglycoside therapy. If concomitant administration is necessary, hydration status as well as renal and vestibular functions should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33874,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Glimepiride",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin secretagogues (e.g., sulfonylureas, meglitinides) may be potentiated by certain drugs, including ACE inhibitors, 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), nonsteroidal anti-inflammatory drugs (NSAIDs), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinine, quinidine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, fibrates, ginseng); stimulating insulin secretion (salicylates, NSAIDs, disopyramide, quinine, quinidine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Or, they may increase plasma concentration of insulin secretagogues by displacing them from plasma protein binding sites and/or inhibiting their metabolism (fibrates, NSAIDs, salicylates, sulfonamides).",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin secretagogues, particularly in patients with advanced age and/or renal impairment. The oral antidiabetic dosage(s) may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their doctor if it occurs. Patients should be observed for loss of glycemic control when these drugs are withdrawn.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33878,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Grepafloxacin",
      "severity": "Moderate",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may potentiate the risk of central nervous system toxicity sometimes associated with fluoroquinolone use. Some investigators suggest that the piperazine ring of fluoroquinolones may inhibit the binding of gamma-aminobutyric acid (GABA) to brain receptors and that NSAIDs may synergistically add to this effect. Patients with a history of seizures may be at greater risk.",
      "management_text": "Clinical monitoring for signs of CNS stimulation such as tremors, involuntary muscle movements, hallucinations, or seizures is recommended if fluoroquinolone antibiotics are prescribed in combination with NSAIDs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33881,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ibandronate",
      "severity": "Moderate",
      "effect": "Theoretical concerns exist regarding the potential for increased risk and severity of gastrointestinal toxicity during coadministration of oral bisphosphonates and nonsteroidal anti-inflammatory drugs (NSAIDs) due to additive or synergistic irritant effects on the gastrointestinal mucosa. Because NSAIDs reduce the rate of ulcer healing in the stomach and duodenum, it is also possible that NSAIDs may delay healing and exaggerate the mucosal injury caused by oral bisphosphonates. Theoretical concerns exist regarding the potential for increased risk and severity of renal impairment during coadministration of bisphosphonates with high dosages or chronic use of NSAIDs due to additive or synergistic nephrotoxic effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure. Cases have primarily involved intravenous formulations of the drugs such as pamidronic acid and zoledronic acid, especially when they are administered too rapidly. The risk of hypocalcemia may also be increased, as drug-induced renal tubular damage can lead to renal loss of calcium and other electrolytes such as magnesium. Bisphosphonates alone often cause mild, asymptomatic hypocalcemia via inhibitive effects on bone resorption and possibly chelation of blood calcium. Chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs) may be associated with renal toxicities including elevations in serum creatinine and BUN, tubular necrosis, glomerulitis, renal papillary necrosis, acute interstitial nephritis, nephrotic syndrome, and renal failure.",
      "management_text": "Caution is advised if bisphosphonates are prescribed in combination with NSAIDs. Patients receiving oral bisphosphonates should be closely monitored for the development of gastrointestinal toxicity and advised to immediately report potential signs and symptoms such as severe abdominal pain, nausea, vomiting, diarrhea, loss of appetite, dizziness, lightheadedness, and/or black, tarry stools. Patients receiving intravenous formulations of bisphosphonates should have renal function and serum electrolytes closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33887,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Icosapent",
      "severity": "Moderate",
      "effect": "Omega-3 fatty acids (e.g., fish oil) may potentiate the pharmacologic effects of anticoagulants and other drugs that affect hemostasis such as platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextran, and nonsteroidal anti-inflammatory drugs (NSAIDs). The exact mechanism of interaction is unknown. Omega-3 fatty acids may possess mild antiplatelet and hypocoagulant activities.",
      "management_text": "In general, patients should consult a healthcare provider before taking any herbal or nutritional supplements. Patients using omega-3 fatty acids in combination with anticoagulants or other drugs that affect hemostasis should be advised of the potential for increased risk of bleeding complications.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33890,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Preliminary evidence suggests that aspirin may increase the plasma free concentration and pharmacologic effects of imipramine by displacing it from plasma protein binding sites.Other salicylates are expected to have similar effects due to their high affinity for plasma proteins.",
      "management_text": "Pharmacologic response to imipramine should be monitored more closely whenever a salicylate is added to or withdrawn from therapy, and the imipramine dosage adjusted as necessary. Patients should be advised to notify their physician if they experience increased adverse effects of imipramine such as dry mouth, constipation, urinary retention, blurred vision, palpitations, and tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33892,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Moderate",
      "effect": "The antiplatelet and cardioprotective effect of low-dose aspirin may be antagonized by coadministration of some nonsteroidal anti-inflammatory drugs (NSAIDs). Ibuprofen has been specifically implicated, and there is evidence that others including indomethacin, naproxen, and tiaprofenic acid may also interact. The mechanism is competitive inhibition of platelet cyclooxygenase by certain NSAIDs, which, unlike aspirin, bind reversibly at the active site of the enzyme and cause a temporary rather than persistent depression of thromboxane formation and thromboxane-dependent platelet function. The combined use of aspirin with NSAIDs in general may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation. Pharmacokinetically, aspirin at anti-inflammatory dosages or higher has been shown to decrease the plasma concentrations of many NSAIDs, including indomethacin and naproxen.",
      "management_text": "Until more information is available, patients receiving low-dose aspirin for cardioprotection should avoid the regular use of NSAIDs including ibuprofen, indomethacin, naproxen, and tiaprofenic acid. Occasional, single use may be acceptable, as the risk from any attenuation of the antiplatelet effect of low-dose aspirin is likely to be minimal given the long-lasting effect of aspirin on platelets. If routine NSAID therapy is necessary, diclofenac may be a viable alternative. In the retrospective study implicating ibuprofen, 75 mg twice daily of delayed-release diclofenac did not interfere with the antiplatelet activity of aspirin. Other noninterfering alternatives for pain include acetaminophen, celecoxib, or narcotic analgesics. In any case, caution is advised whenever aspirin is combined with a NSAID due to the potential for additive GI toxicity. Patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as abdominal pain, bloating, sudden dizziness or lightheadedness, nausea, vomiting, hematemesis, anorexia, and melena.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33893,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Insulin human",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33895,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Insulin glargine",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33900,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Insulin lispro",
      "severity": "Moderate",
      "effect": "The hypoglycemic effect of insulin may be potentiated by certain drugs, including ACE inhibitors, angiotensin receptor blockers (ARBs), 4-aminoquinolines, amylin analogs, anabolic steroids, fibrates, monoamine oxidase inhibitors (MAOIs, including linezolid), salicylates, selective serotonin reuptake inhibitors (SSRIs), sulfonamides, disopyramide, propoxyphene, quinidine, quinine, and ginseng. These drugs may increase the risk of hypoglycemia by enhancing insulin sensitivity (ACE inhibitors, ARBs, fibrates, ginseng); stimulating insulin secretion (salicylates, disopyramide, pentoxifylline, propoxyphene, quinidine, quinine, MAOIs, ginseng); decreasing insulin clearance and resistance (4-aminoquinolines); increasing peripheral glucose utilization (SSRIs, insulin-like growth factor); inhibiting gluconeogenesis (SSRIs, MAOIs, insulin-like growth factor); slowing the rate of gastric emptying (amylin analogs); and/or suppressing postprandial glucagon secretion (amylin analogs). Clinical hypoglycemia has been reported during use of some of these agents alone or with insulin and/or insulin secretagogues.",
      "management_text": "Close monitoring for the development of hypoglycemia is recommended if these drugs are coadministered with insulin, particularly in patients with advanced age and/or renal impairment. The insulin dosage may require adjustment if an interaction is suspected. Patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33904,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Isradipine",
      "severity": "Moderate",
      "effect": "Limited data indicate that some cyclooxygenase inhibitors may attenuate the antihypertensive effects of some calcium channel blockers. The mechanism appears to be related to an alteration of vascular tone, which is dependent on prostacyclins and other vasodilatory prostanoids. When a nonsteroidal anti-inflammatory drug (NSAID) is added to the regimen of a patient who is already taking a calcium channel blocker, increased blood pressure may result. Also, the clinician should be aware that the risk of hypotension is increased when NSAIDs are withdrawn from the regimen.",
      "management_text": "Monitoring for altered blood pressure control is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33911,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Moderate",
      "effect": "The combined use of low-dose or high-dose aspirin with other nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the potential for serious gastrointestinal (GI) toxicity, including inflammation, bleeding, ulceration, and perforation. Aspirin at anti-inflammatory dosages or higher may also decrease the plasma concentrations of many NSAIDs. The decreases have ranged from none or small (piroxicam, meloxicam, naproxen, tolmetin) to substantial (flurbiprofen, ibuprofen). However, the therapeutic response does not appear to be affected.",
      "management_text": "Caution is advised if aspirin, particularly at anti-inflammatory dosages, is used with other NSAIDs. Concomitant administration of NSAIDs is considered contraindicated or not recommended with aspirin at analgesic/anti-inflammatory dosages by many NSAID manufacturers. During concomitant therapy, patients should be advised to take the medications with food and to immediately report signs and symptoms of GI ulceration and bleeding such as abdominal pain, bloating, sudden dizziness or lightheadedness, nausea, vomiting, hematemesis, anorexia, and melena.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34082,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Eptifibatide",
      "severity": "Moderate",
      "effect": "Although aspirin is routinely given with glycoprotein IIb/IIIa inhibitors, be cognizant of the increased risk of bleeding associated with this combination due to the additive inhibitory effects of salicylates on platelet function.",
      "management_text": "It is recommended that these drugs be used together only when indicated by skilled personnel who are qualified and equipped to detect and treat bleeding complications. Patients should be closely monitored for signs of bleeding, especially at arterial puncture sites. Therapy should be discontinued immediately if serious or uncontrollable bleeding or thrombocytopenia occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34111,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Alemtuzumab",
      "severity": "Moderate",
      "effect": "Coadministration of alemtuzumab with antiplatelet or anticoagulant drugs may increase the risk of bleeding. Use of alemtuzumab alone has been associated with autoimmune and hemolytic anemia, thrombocytopenia, prolonged myelosuppression, bone marrow aplasia, hemophilia, and pancytopenia. The mechanism for this interaction has not been clearly delineated, but is presumably due to additive antiplatelet/anticoagulant effects.",
      "management_text": "Caution is recommended if alemtuzumab is used concomitantly with antiplatelet or anticoagulant drugs. Patients should be monitored for increased anticoagulant effects and bleeding complications. Patients should be advised to promptly report any signs of unusual bleeding or bruising to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 189886,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Minor",
      "effect": "Salicylates may increase the potential for phenytoin toxicity (the active metabolite of fosphenytoin). The mechanism is competitive displacement of phenytoin from plasma protein binding sites. Caution is recommended if these drugs must be used together. Additionally, total plasma concentrations of phenytoin should be interpreted cautiously if a patient is taking aspirin, or other salicylates, because a greater amount of free drug may be present.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 15115,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Minor",
      "effect": "High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33804,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Chamomile",
      "severity": "Minor",
      "effect": "Some herbs such as chamomile and fenugreek have coumarin constituents. Theoretically, ingesting large quantities of these herbs may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. However, their effects on the coagulation system have not been studied, and bleeding complications have not been reported in humans. Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used chamomile or fenugreek extensively prior to receiving anticoagulation, antiplatelet or thrombolytic therapy, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33805,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cholestyramine",
      "severity": "Minor",
      "effect": "Although cholestyramine does not reduce salicylate absorption, it may delay the time to peak salicylate concentrations. Separation of cholestyramine and salicylate doses by three to four hours is recommended.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33808,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dexlansoprazole",
      "severity": "Minor",
      "effect": "Coadministration with proton pump inhibitors may decrease the oral bioavailability of aspirin and other salicylates. Proton pump inhibitors may enhance the release rate of salicylates from enteric-coated formulations due to premature disruption of the coating and intragastric release of the drug secondary to an increase in gastric pH. The clinical significance of this interaction is unknown. Theoretically, it may increase the risk of gastric adverse effects associated with salicylates.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33832,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Hyaluronidase",
      "severity": "Minor",
      "effect": "Larger amounts of hyaluronidase may be required to achieve equivalent dispersing effects if patients are concomitantly receiving large doses of salicylates, cortisone, ACTH, estrogens, or antihistamines. These drugs may render tissues partially resistant to the dispersing action of hyaluronidase.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33885,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Capsicum",
      "severity": "Minor",
      "effect": "Theoretically, capsicum may potentiate the risk of bleeding in patients treated with agents that affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, or agents that commonly cause thrombocytopenia. Animal and limited human data suggest that capsicum may increase fibrinolytic activity, lower plasma fibrinogen levels, increase plasma antithrombin III levels, inhibit platelet aggregation, and prolong bleeding time. In patients who have used capsicum extensively prior to receiving anticoagulation, antiplatelet, or thrombolytic therapy, the potential for an interaction should be considered. Clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 149409,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Clove",
      "severity": "Minor",
      "effect": "Clove and clove oil may potentiate the effects of anticoagulants and other drugs that may affect hemostasis such as platelet inhibitors, thrombolytic agents, and nonsteroidal anti-inflammatory drugs, possibly increasing the risk of bleeding. Eugenol, the active constituent of clove and clove oil, has been shown to be an inhibitor of platelet activity.",
      "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. In patients who have used clove and clove oil extensively prior to receiving treatment with anticoagulants or other drugs that may affect hemostasis, the potential for an interaction should be considered. Close clinical and laboratory observation for hematologic complications is recommended. Patients should be advised to promptly report any signs of bleeding to their physician, including pain, swelling, headache, dizziness, weakness, prolonged bleeding from cuts, increased menstrual flow, vaginal bleeding, nosebleeds, bleeding of gums from brushing, unusual bleeding or bruising, red or brown urine, or red or black stools.",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 149410,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Caffeine",
      "severity": "Minor",
      "effect": "One study has reported that coadministration of caffeine and aspirin lead to a 25% increase in the rate of appearance and 17% increase in maximum concentration of salicylate in the plasma. A significantly higher area under the plasma concentration time curve of salicylate was also reported when both drugs were administered together. The exact mechanism of this interaction has not been specified. Physicians and patients should be aware that coadministration of aspirin and caffeine may lead to higher salicylate levels faster.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 4579,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Minor",
      "effect": "Salicylates in anti-inflammatory dosages may blunt the diuretic and natriuretic response to loop diuretics.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 15463,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Bisoprolol",
      "severity": "Minor",
      "effect": "High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33789,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Bumetanide",
      "severity": "Minor",
      "effect": "Salicylates in anti-inflammatory dosages may blunt the diuretic and natriuretic response to loop diuretics.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33795,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Carteolol",
      "severity": "Minor",
      "effect": "High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33803,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Desmopressin",
      "severity": "Minor",
      "effect": "Limited data have shown that desmopressin (DDAVP) can significantly reduce aspirin-induced increases in bleeding times. The DDAVP effect on bleeding time correlates closely with increases in the plasma concentration of von Willebrand factor. The clinical consequences of this interaction are not known.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33828,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Donepezil",
      "severity": "Minor",
      "effect": "Donepezil may increase gastric acid secretion by increasing cholinergic activity. The risk for gastrointestinal bleeding is, therefore, theoretically increased in patients receiving donepezil in combination with a nonsteroidal anti-inflammatory agent. Caution is recommended when this combination is used.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33842,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Esmolol",
      "severity": "Minor",
      "effect": "High doses of salicylates may blunt the antihypertensive effects of beta-blockers. The proposed mechanism is inhibition of prostaglandin synthesis. Low-dose aspirin does not appear to affect blood pressure. In addition, beta-blockers may exert an antiplatelet effect, which may be additive with the effects of some salicylates. Metoprolol may also increase aspirin absorption and/or plasma concentrations of salicylates; however, the clinical significance of this effect is unknown. Data have been conflicting. Until more information is available, patients who require concomitant therapy should be monitored for altered antihypertensive response whenever a salicylate is introduced or discontinued, or when its dosage is modified.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33859,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Esomeprazole",
      "severity": "Minor",
      "effect": "Coadministration with proton pump inhibitors may decrease the oral bioavailability of aspirin and other salicylates. Proton pump inhibitors may enhance the release rate of salicylates from enteric-coated formulations due to premature disruption of the coating and intragastric release of the drug secondary to an increase in gastric pH. The clinical significance of this interaction is unknown. Theoretically, it may increase the risk of gastric adverse effects associated with salicylates.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33860,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Etacrynic acid",
      "severity": "Minor",
      "effect": "Salicylates in anti-inflammatory dosages may blunt the diuretic and natriuretic response to loop diuretics.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33861,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Griseofulvin",
      "severity": "Minor",
      "effect": "One pediatric case report has suggested that griseofulvin may decrease serum salicylate (aspirin) concentrations. The mechanism suggested by the authors is interference with salicylate absorption. The authors have recommended that griseofulvin be avoided if possible when therapy with anti-inflammatory doses of salicylate are required. If these drugs must be given together, staggered doses and careful monitoring of salicylate levels are recommended.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 33882,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fulvestrant",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223300,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223301,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Isoniazid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223302,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223304,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Desloratadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223306,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ezetimibe",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223310,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dipyridamole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223311,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Formoterol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223313,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Exemestane",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223315,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223317,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223318,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cromoglicic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223319,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ganciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223320,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Hydroxyurea",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223321,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cinacalcet",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223323,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Isosorbide mononitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223325,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223331,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fluocinonide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223336,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223338,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fludarabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223341,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fluvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223346,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Capecitabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223348,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cefuroxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223350,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dutasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223351,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cefadroxil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223354,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223355,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cefprozil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223357,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Calcium chloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223359,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223360,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ciclopirox",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223365,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Clindamycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223366,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Flecainide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223367,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223371,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ceftriaxone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223372,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223373,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Finasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223374,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Aminophylline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223375,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Gemfibrozil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223379,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223380,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Iodixanol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223381,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fosamprenavir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223384,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cefazolin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223385,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cefepime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223389,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cefpodoxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223390,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223395,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Calcipotriol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223397,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ambrisentan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223398,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Iopamidol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223399,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ioversol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223400,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Iopromide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223401,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Clobetasol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223403,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fluticasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223404,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Alosetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224185,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cytarabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224648,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225288,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Amoxicillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228035,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230450,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Amifostine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231241,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231524,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Anastrozole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233674,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "gamma-Aminobutyric acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236134,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Galactose",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236701,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cladribine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198173,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201240,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Alfuzosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 202886,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204349,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ampicillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204643,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Chloramphenicol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205660,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Aminocaproic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208496,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Adenosine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213302,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Epinephrine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214279,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Amphotericin B",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214780,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Alprostadil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217625,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Estradiol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218000,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Acyclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218360,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Amantadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222275,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Goserelin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223097,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cyanocobalamin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223099,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Calcitriol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223100,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Folic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223101,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Flunisolide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223103,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223106,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223109,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223111,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Hydroxocobalamin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223112,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223114,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Eletriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223117,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Gadodiamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223118,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cabergoline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223126,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dapsone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223127,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Doxycycline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223128,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Clotrimazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223129,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Disopyramide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223132,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Etomidate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223137,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Bupivacaine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223139,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ertapenem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223140,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Chlorthalidone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223141,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223143,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223145,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ethambutol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223146,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cetirizine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223151,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223155,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Carisoprodol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223162,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Famciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223172,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Allopurinol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223174,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Ceftazidime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223175,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cerivastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223176,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Gemcitabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223178,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Chlordiazepoxide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223183,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Chlorpromazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223184,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Brimonidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223187,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Buspirone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223188,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cefotaxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223189,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Entacapone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223190,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Darifenacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223192,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Flutamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223194,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223195,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223196,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223199,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Erlotinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223202,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223203,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cefdinir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223204,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Gadoversetamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223205,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fluorouracil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223208,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223211,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Bosentan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223212,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223213,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223214,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Clonidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223216,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Doxazosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223221,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Amiloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223222,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223224,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223225,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223227,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Galantamine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223237,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223240,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Imiquimod",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223246,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Isoflurane",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223252,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dolasetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223254,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Irinotecan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223257,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Etoposide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223260,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Alfentanil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223264,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dicyclomine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223265,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Indapamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223266,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223268,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223271,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cefaclor",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223272,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dobutamine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223274,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Dacarbazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223277,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Chlorhexidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223284,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Isosorbide dinitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223285,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Granisetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223286,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Buprenorphine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223295,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223296,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223297,
      "ingredient1": "Acetylsalicylic acid"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 2280,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dihydrocodeine",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 4654,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5018,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Alvimopan",
      "severity": "Major",
      "effect": "Recent exposure to opioids can increase the sensitivity to mu opioid receptor antagonists.",
      "management_text": "The use of alvimopan is contraindicated in patients who have received therapeutic doses of opioids for more than 7 consecutive days immediately prior to alvimopan administration. Caution is advised in patients who have received more than 3 doses of an opioid within the week prior to surgery, as these patients were not studied in the postoperative ileus clinical trials. Patients with recent exposure to opioids should be monitored for increased adverse effects such as abdominal pain, nausea and vomiting, and diarrhea.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5019,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Amobarbital",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5025,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5103,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dantrolene",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5107,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dezocine",
      "severity": "Major",
      "effect": "Concomitant use of opioids with other central nervous system (CNS) depressants including mixed agonist-antagonist or partial agonist opioids may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased.",
      "management_text": "The use of opioids in conjunction with other CNS depressants including mixed agonist-antagonist or partial agonist opioids should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary (e.g., when initiating a switch from one opioid to the other), the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, and patients should be closely monitored for signs and symptoms of CNS and respiratory depression. Additional caution is advisable when a mixed agonist-antagonist or partial agonist opioid is added to an existing opioid regimen, as there may be an increased risk of withdrawal symptoms (e.g., restlessness, insomnia, sweating, lacrimation, or rhinorrhea) following initiation of the mixed agonist-antagonist or partial agonist opioid.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5120,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5121,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Droperidol",
      "severity": "Major",
      "effect": "The use of droperidol has been associated with QT interval prolongation, torsade de pointes and other serious arrhythmias, and sudden death. The concurrent administration of agents that can produce bradycardia, a known risk factor for QT interval prolongation, such as benzodiazepines and opiates, particularly intravenous opiates, may increase the risk of QT interval prolongation. In addition, hypotensive effects and central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking droperidol with benzodiazepines or opiates, especially in elderly or debilitated patients.",
      "management_text": "Extreme caution and close monitoring are recommended if droperidol must be administered concomitantly with other bradycardic drugs. The dosage of droperidol should be individualized and titrated to the desired effect. Routine vital sign and ECG monitoring is recommended. When droperidol is used in combination with benzodiazepines or opiates, patients should be monitored for potentially excessive or prolonged CNS or respiratory depression as well as severe hypotension. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their doctor if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5135,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5149,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Eszopiclone",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5150,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Fluphenazine",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5163,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5164,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Major",
      "effect": "Concomitant use of opioids with gabapentinoids (e.g., gabapentin, pregabalin) may increase the risk of opioid overdose and serious adverse effects such as profound sedation, respiratory depression, syncope, and death due to potentially additive depressant effects on the central nervous system. Coadministration with opioids may increase the oral bioavailability of gabapentin.",
      "management_text": "Caution is advised when opioids and gabapentinoids are coadministered, particularly in patients with additional risk factors for respiratory depression such as advanced age, renal insufficiency, or chronic lung disease. The dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Use of additional central nervous system depressants should be avoided if possible. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery until they know how these medications affect them. For patients who have been receiving extended therapy with both an opioid and a gabapentinoid (either for analgesia or seizure control) and require discontinuation of either medication, a gradual tapering of dose is advised, since abrupt withdrawal may lead to withdrawal symptoms and increased seizure risk.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5171,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Halazepam",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5181,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5183,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Diamorphine",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5185,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Hydrocodone",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5188,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5190,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5192,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Iloperidone",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5195,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Iohexol",
      "severity": "Major",
      "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.",
      "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5198,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Iopamidol",
      "severity": "Major",
      "effect": "Intrathecal administration of iodinated contrast media may induce seizures. Although clinical data are generally lacking, there may be a theoretical risk of increased seizure potential when used with selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), and/or any substance that can reduce the seizure threshold (e.g., carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, theophylline). These agents are often individually epileptogenic and may have additive effects when combined.",
      "management_text": "Drugs that can lower the seizure threshold should preferably be withheld for at least 48 hours prior to and 24 hours following intrathecal administration of iodinated contrast media, provided that temporary interruption of therapy does not pose an undue risk to the patient. Otherwise, close monitoring is advised during and after contrast administration.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5199,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Isocarboxazid",
      "severity": "Major",
      "effect": "Coadministration of narcotic analgesics with monoamine oxidase inhibitors (MAOIs) has been associated with rare reports of anxiety, confusion, hypotension, respiratory depression, cyanosis, and coma. The mechanism of interaction is unknown, but may involve potentiation of central nervous system (CNS) and respiratory depressant effects by MAOIs.",
      "management_text": "Narcotic analgesics should generally not be used with MAOIs or other agents that possess MAOI activity (e.g., furazolidone, linezolid, methylene blue, procarbazine). At least 14 days should elapse between discontinuation of MAOI therapy and initiation of treatment with opioids.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5201,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dextropropoxyphene",
      "severity": "Major",
      "effect": "Sedatives, tranquilizers, muscle relaxants, antidepressants, and other central nervous system (CNS) depressants may have additive CNS- and/or respiratory-depressant effects with propoxyphene. Misuse of propoxyphene, either alone or in combination with other CNS depressants, has been a major cause of drug-related deaths, particularly in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Pharmacokinetically, propoxyphene is an inhibitor of CYP450 2D6 and may increase the plasma concentrations of many psychotropic agents that are metabolized by the isoenzyme such as phenothiazines, haloperidol, risperidone, phenobarbital, and some tricyclic antidepressants and serotonin reuptake inhibitors.",
      "management_text": "Caution is advised if propoxyphene is used with sedatives, tranquilizers, muscle relaxants, antidepressants, and other CNS depressants, particularly in the elderly and in patients with a history of emotional disturbances, suicidal ideation, or alcohol and drug abuse. Dosage reductions may be appropriate. Patients should be monitored for potentially excessive or prolonged CNS and respiratory depression and other CNS adverse effects. Patients should be warned not to exceed recommended dosages, to avoid alcohol, and to avoid activities requiring mental alertness until they know how these agents affect them.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5340,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dichloralphenazone",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5490,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Ethchlorvynol",
      "severity": "Major",
      "effect": "Concomitant use of opioids with benzodiazepines or other central nervous system (CNS) depressants (e.g., nonbenzodiazepine sedatives/hypnotics, anxiolytics, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol) may result in profound sedation, respiratory depression, coma, and death. The risk of hypotension may also be increased with some CNS depressants (e.g., alcohol, benzodiazepines, phenothiazines).",
      "management_text": "The use of opioids in conjunction with benzodiazepines or other CNS depressants should generally be avoided unless alternative treatment options are inadequate. If coadministration is necessary, the dosage and duration of each drug should be limited to the minimum required to achieve desired clinical effect, with cautious titration and dosage adjustments when needed. Patients should be monitored closely for signs and symptoms of respiratory depression and sedation, and advised to avoid driving or operating hazardous machinery.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 5151,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Abiraterone",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 1353,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Alfentanil",
      "severity": "Moderate",
      "effect": "Potent narcotics, when used as an adjuvant in patients receiving alfentanil, remifentanil, or sufentanil for anesthesia or conscious sedation, may further decrease cardiac output and respiratory drive.",
      "management_text": "The dosage of alfentanil, remifentanil, or sufentanil may need to be decreased in patients who have received large doses of narcotics.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5015,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Alfuzosin",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5016,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Almotriptan",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5017,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Amifampridine",
      "severity": "Moderate",
      "effect": "The use of amifampridine is associated with a dose-related risk of seizures, and the risk may be further increased when coadministered with other drugs that can reduce the seizure threshold. Seizures have occurred in patients without a history of seizures taking amifampridine at recommended dosages and at various times after initiation of treatment.",
      "management_text": "Caution is advised if amifampridine is coadministered with any substance that can reduce the seizure threshold, particularly in the elderly and in patients with other risk factors for seizures (e.g., head trauma; brain tumor; severe hepatic cirrhosis; metabolic disorders; CNS infections; excessive use of alcohol or sedatives; addiction to opiates, cocaine, or stimulants; diabetes treated with oral hypoglycemic agents or insulin). Consider discontinuation or dose reduction of amifampridine in patients who experience a seizure during treatment. Use of amifampridine is contraindicated in patients with a history of seizures.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5020,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Amiloride",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5021,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5022,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Amitriptyline",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5023,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Amlodipine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5024,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Amoxapine",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5026,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Amyl Nitrite",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5027,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Cyclizine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5102,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Cyproheptadine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5104,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dabrafenib",
      "severity": "Moderate",
      "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels. This interaction may lead to reduced codeine efficacy and potentially initiate the onset of withdrawal symptoms in patients who are physically dependent. In addition, patients may be at an increased risk of CNS and/or respiratory-depressant effects from increased levels of codeine once concomitant therapy with the CYP450 3A4 inducer is ceased.",
      "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended. Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5105,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dacomitinib",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5106,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Darifenacin",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5108,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Delavirdine",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5109,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Desflurane",
      "severity": "Moderate",
      "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.",
      "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5110,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Desipramine",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5111,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Desvenlafaxine",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5113,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Deutetrabenazine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5114,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Moderate",
      "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels. This interaction may lead to reduced codeine efficacy and potentially initiate the onset of withdrawal symptoms in patients who are physically dependent. In addition, patients may be at an increased risk of CNS and/or respiratory-depressant effects from increased levels of codeine once concomitant therapy with the CYP450 3A4 inducer is ceased.",
      "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended. Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5115,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dexbrompheniramine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5116,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dexfenfluramine",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5117,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dexmedetomidine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5118,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dextromethorphan",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5119,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Diazoxide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5122,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dicyclomine",
      "severity": "Moderate",
      "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.",
      "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5123,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5124,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dimenhydrinate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5125,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Diphenhydramine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5126,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dolasetron",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5128,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Doxazosin",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5129,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Doxepin",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5130,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Doxylamine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5132,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dronabinol",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5133,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Dronedarone",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5134,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5136,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Eliglustat",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5138,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Eluxadoline",
      "severity": "Moderate",
      "effect": "The risk of constipation and serious constipation-related adverse reactions may be increased when eluxadoline is used with other drugs that are also associated with this adverse effect.",
      "management_text": "Concomitant use of eluxadoline with other drugs that can cause constipation such as alosetron, anticholinergics, and opioids should generally be avoided. Loperamide may be used occasionally for acute management of severe diarrhea, but chronic use is not recommended, and it should be discontinued immediately if constipation occurs. Eluxadoline should also be discontinued if constipation occurs for more than 4 days.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5139,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5140,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Entacapone",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5142,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Enzalutamide",
      "severity": "Moderate",
      "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels. This interaction may lead to reduced codeine efficacy and potentially initiate the onset of withdrawal symptoms in patients who are physically dependent. In addition, patients may be at an increased risk of CNS and/or respiratory-depressant effects from increased levels of codeine once concomitant therapy with the CYP450 3A4 inducer is ceased.",
      "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended. Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5143,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Eprosartan",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5144,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Escitalopram",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5145,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Esketamine",
      "severity": "Moderate",
      "effect": "Concomitant use of esketamine with central nervous system (CNS) depressants may increase sedation and impairment of attention, judgment, thinking, reaction speed, and psychomotor skills.",
      "management_text": "Caution is advised and patients should be closely monitored during concomitant use of esketamine with CNS depressants. Due to the risk of delayed or prolonged sedation and other adverse effects, patients should be monitored for at least 2 hours after esketamine administration, followed by an assessment to determine when the patient is considered clinically stable and ready to leave the healthcare setting. Patients should be instructed not to engage in potentially hazardous activities, such as driving a motor vehicle or operating machinery, until the next day after a restful sleep.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5146,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Eslicarbazepine",
      "severity": "Moderate",
      "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels. This interaction may lead to reduced codeine efficacy and potentially initiate the onset of withdrawal symptoms in patients who are physically dependent. In addition, patients may be at an increased risk of CNS and/or respiratory-depressant effects from increased levels of codeine once concomitant therapy with the CYP450 3A4 inducer is ceased.",
      "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended. Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5147,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Ethosuximide",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5152,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Etravirine",
      "severity": "Moderate",
      "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels. This interaction may lead to reduced codeine efficacy and potentially initiate the onset of withdrawal symptoms in patients who are physically dependent. In addition, patients may be at an increased risk of CNS and/or respiratory-depressant effects from increased levels of codeine once concomitant therapy with the CYP450 3A4 inducer is ceased.",
      "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended. Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5153,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Ezogabine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5154,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Fedratinib",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5155,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Felbamate",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5156,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Felodipine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5157,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Fenfluramine",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5158,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Fesoterodine",
      "severity": "Moderate",
      "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.",
      "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5159,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Flavoxate",
      "severity": "Moderate",
      "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.",
      "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5160,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Flibanserin",
      "severity": "Moderate",
      "effect": "The central nervous system (CNS) effects of flibanserin such as somnolence and fatigue may be potentiated by concomitant use of other agents with CNS depressant effects. The risk of CNS depression is increased if flibanserin is taken during waking hours or with alcohol or other CNS depressants.",
      "management_text": "Patients receiving flibanserin with other agents that can cause CNS depression should be apprised of the potential for increased adverse effects such as drowsiness, dizziness, lightheadedness, and fatigue. Patients should not drive, operate machinery, or engage in hazardous activities requiring mental alertness and motor coordination for at least 6 hours after taking flibanserin.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5161,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Fluoxetine",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5162,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Fosinopril",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5166,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Fospropofol",
      "severity": "Moderate",
      "effect": "Additive central nervous system and cardiorespiratory depressant effects may occur when fospropofol or propofol is administered with other depressants such as sedative-hypnotic agents and narcotic analgesics.",
      "management_text": "Patients should be monitored closely for excessive sedation and cardiorespiratory depression, and the medication dosage(s) adjusted accordingly. Supportive therapy should be provided if needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5167,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Fostamatinib",
      "severity": "Moderate",
      "effect": "Coadministration with fostamatinib may increase the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme and/or P-glycoprotein (P-gp) transporter. The proposed mechanism is decreased clearance in the intestine and/or liver due to inhibition of CYP450 3A4-mediated metabolism and P-gp-mediated efflux by fostamatinib.",
      "management_text": "Caution is advised when fostamatinib is used concurrently with drugs that are known substrates of CYP450 3A4 and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fostamatinib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5168,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Frovatriptan",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5169,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5170,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Galantamine",
      "severity": "Moderate",
      "effect": "Coadministration with drugs that are inhibitors of CYP450 2D6 may increase the plasma concentrations of galantamine, which is primarily metabolized by the isoenzyme. In multiple-dose pharmacokinetic studies, a potent inhibitor such as paroxetine has been shown to increase the area under the plasma concentration-time curve (AUC) of galantamine by 40%.",
      "management_text": "During concomitant therapy with drugs that inhibit CYP450 2D6 activity, the possibility of prolonged and/or increased pharmacologic effects of galantamine should be considered. Patients should be advised to notify their physician if they experience nausea, vomiting, sweating, weakness, salivation, or slower respirations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5172,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Ginkgo biloba",
      "severity": "Moderate",
      "effect": "Certain preparations of ginkgo biloba have been reported to induce seizures. There may be a theoretical risk of increased seizure potential when used with other agents that can lower the seizure threshold such as selective serotonin reuptake inhibitors (SSRI antidepressants or anorectics), monoamine oxidase inhibitors, neuroleptic agents, central nervous system stimulants, opioids, tricyclic antidepressants, other tricyclic compounds (e.g., cyclobenzaprine, phenothiazines), carbapenems, cholinergic agents, fluoroquinolones, interferons, chloroquine, mefloquine, lindane, and theophylline. Ginkgo products may contain varying amounts of 4'-O-methylpyridoxine (ginkgotoxin), a known neurotoxin found primarily in ginkgo biloba seeds but also detected in lesser amounts in the leaves. In vivo, 4'-O-methylpyridoxine competes with vitamin B6, which causes an indirect inhibition of glutamate decarboxylase and subsequent decrease in the formation of gamma-aminobutyric acid (GABA) in the brain. There have been published case reports of generalized convulsions and vomiting within several hours after ingestion of large amounts of ginkgo nuts/seeds, including in young children and healthy individuals with no known personal or family history of epilepsy.",
      "management_text": "Patients should consult a healthcare provider before taking any herbal or alternative medicine. Because of inconsistencies in formulation and potency of commercial herbal preparations, there is no way to verify without laboratory testing if and in what quantity 4'-O-methylpyridoxine may be present in a given ginkgo preparation. Patients treated with agents that can lower the seizure threshold should preferably avoid the use of products containing ginkgo biloba.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5174,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Givosiran",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5175,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Glycerol phenylbutyrate",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5176,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Glycopyrronium",
      "severity": "Moderate",
      "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.",
      "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5177,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Goldenseal",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5178,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Granisetron",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5179,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Guanethidine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5180,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Halofantrine",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5182,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Halothane",
      "severity": "Moderate",
      "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.",
      "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5184,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Hydralazine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5186,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5187,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Hydroflumethiazide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5189,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5191,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Hyoscyamine",
      "severity": "Moderate",
      "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects. The risk and/or severity of adverse effects such as sedation, dizziness, confusion, cognitive and psychomotor impairment, dry mouth, constipation, and urinary retention may increase. Severe constipation may lead to paralytic ileus in some cases.",
      "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5193,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Moderate",
      "effect": "Centrally-acting agents such as antiemetics, sedatives, narcotics, or antihistamines may add to the neurotoxic effects of ifosfamide. Administration of ifosfamide can cause CNS toxicity, which necessitates careful monitoring of the patient. Neurologic manifestations include somnolence, confusion, hallucinations, blurred vision, psychotic behavior, extrapyramidal symptoms, urinary incontinence, seizures, and in some instances, coma. There have also been reports of peripheral neuropathy. Ifosfamide neurotoxicity may occur within a few hours to a few days after initial administration and typically resolves within 48 to 72 hours of ifosfamide discontinuation.",
      "management_text": "Due to the potential for additive effects, centrally-acting agents should be used with caution in combination with ifosfamide. If ifosfamide-induced encephalopathy occurs, both ifosfamide and non-essential concomitant CNS agents should be discontinued. Supportive therapy should be initiated and maintained until complete resolution of neurotoxicity.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5194,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Imipramine",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5196,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Indapamide",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5197,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5200,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Isoflurane",
      "severity": "Moderate",
      "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.",
      "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5202,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Isosorbide dinitrate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5203,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Isosorbide mononitrate",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5204,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Alimemazine",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5414,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "Ethanol may potentiate the central nervous system (CNS) depressant effects of opioid analgesics. Concomitant use may result in additive CNS depression and impairment of judgment, thinking, and psychomotor skills. In more severe cases, hypotension, respiratory depression, profound sedation, coma, or even death may occur.",
      "management_text": "Concomitant use of opioid analgesics with ethanol should be avoided.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12510,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Efavirenz",
      "severity": "Moderate",
      "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels. This interaction may lead to reduced codeine efficacy and potentially initiate the onset of withdrawal symptoms in patients who are physically dependent. In addition, patients may be at an increased risk of CNS and/or respiratory-depressant effects from increased levels of codeine once concomitant therapy with the CYP450 3A4 inducer is ceased.",
      "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended. Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73241,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Ethotoin",
      "severity": "Moderate",
      "effect": "Central nervous system- and/or respiratory-depressant effects may be additively or synergistically increased in patients taking multiple drugs that cause these effects, especially in elderly or debilitated patients.",
      "management_text": "During concomitant use of these drugs, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression. Cautious dosage titration may be required, particularly at treatment initiation. Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73242,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Fosphenytoin",
      "severity": "Moderate",
      "effect": "Coadministration of codeine with potent or moderate CYP450 3A4 inducers may result in lower codeine plasma concentrations, higher levels of the inactive metabolite norcodeine, and less metabolism via CYP450 2D6, resulting in lower morphine levels. This interaction may lead to reduced codeine efficacy and potentially initiate the onset of withdrawal symptoms in patients who are physically dependent. In addition, patients may be at an increased risk of CNS and/or respiratory-depressant effects from increased levels of codeine once concomitant therapy with the CYP450 3A4 inducer is ceased.",
      "management_text": "The potential loss of efficacy of codeine or dihydrocodeine and onset of opioid withdrawal symptoms should be considered when used in combination with a potent or moderate CYP450 3A4 inducer. Alternative agents with no or minimal CYP450 3A4 induction potential are recommended whenever possible. If concomitant use is considered necessary, caution and close clinical and laboratory monitoring are recommended. Dosage adjustments may also be required whenever a CYP450 3A4 inducer is added to or withdrawn from therapy. Following discontinuation of a CYP450 3A4 inducer, patients should be monitored for potentially excessive or prolonged CNS and respiratory depression.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73243,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Imatinib",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73244,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Eplerenone",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 289211,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Guanfacine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation.  Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents.  Some authorities recommend avoiding alcohol in patients receiving vasodilating antihypertensive drugs.  Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 289212,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Diphenoxylate",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 293761,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Difenoxin",
      "severity": "Moderate",
      "effect": "Coadministration of narcotic analgesics with antidiarrheal agents may have additive central nervous system (CNS) and gastrointestinal (GI) system effects, and increase the risk of severe constipation or paralytic ileus and CNS depression.",
      "management_text": "If concomitant use cannot be avoided, patients should be monitored for potentially excessive or prolonged CNS depression and constipation.  Ambulatory patients should be counseled to avoid activities requiring mental alertness until they know how these agents affect them.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 298603,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Homatropine",
      "severity": "Moderate",
      "effect": "Coadministration of opioids with anticholinergic agents may result in additive central nervous system (CNS), gastrointestinal, and genitourinary effects.",
      "management_text": "Caution and close monitoring of central nervous system, gastrointestinal, and genitourinary adverse effects are recommended when opioids are used with anticholinergic agents.  Ambulatory patients should be counseled to avoid hazardous activities requiring mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 300403,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Desmopressin",
      "severity": "Moderate",
      "effect": "Coadministration with opiates may increase the plasma concentrations and pharmacologic effects of oral desmopressin. The risk of water intoxication and/or hyponatremia may be increased.",
      "management_text": "Caution is recommended if desmopressin is used in combination with opiates. Serum electrolytes, especially sodium, as well as BUN and creatinine should be monitored regularly. Patients should be advised to seek immediate medical attention if they develop early signs and symptoms of water intoxication or hyponatremia such as anorexia, nausea, vomiting, drowsiness, lethargy, weakness, listlessness, headache, confusion, difficulty concentrating, memory impairment, anuria, and weight gain. Early treatment may help prevent progression to seizure, coma, respiratory arrest, and death.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5112,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Eletriptan",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5137,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Enflurane",
      "severity": "Moderate",
      "effect": "Opioids may be expected to decrease the minimum alveolar concentration required for inhalation anesthetics. When these agents are used concomitantly, less inhalation anesthetic may be required.",
      "management_text": "In general, anesthesia should be titrated to clinical effect by those experienced in anesthesia technique and in the care of patients receiving opioids.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5141,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Esmolol",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5148,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Fluvoxamine",
      "severity": "Moderate",
      "effect": "Opioids may potentiate the effects of serotonergic agents and increase the risk of serotonin syndrome. Serotonin syndrome is a rare but serious and potentially fatal condition thought to result from hyperstimulation of brainstem 5-HT1A and 2A receptors. Symptoms of the serotonin syndrome may include mental status changes such as irritability, altered consciousness, confusion, hallucinations, and coma; autonomic dysfunction such as tachycardia, hyperthermia, diaphoresis, shivering, blood pressure lability, and mydriasis; neuromuscular abnormalities such as hyperreflexia, myoclonus, tremor, rigidity, and ataxia; and gastrointestinal symptoms such as abdominal cramping, nausea, vomiting, and diarrhea. Since many serotonergic agents can also cause central nervous system depression, concomitant use with opioids may result in increased sedation and impairment of judgment, thinking, and psychomotor skills.",
      "management_text": "Caution is advised when opioids are used concomitantly with serotonergic agents such as selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), other antidepressants/psychotropic agents (e.g., amoxapine, buspirone, lithium, maprotiline, mirtazepine, nefazodone, trazodone, vilazodone), 5-HT1 receptor agonists (triptans), 5-HT3 receptor antagonists, cyclobenzaprine, dextromethorphan, 5-hydroxytryptophan, and St. John's wort. Patients should be monitored for symptoms of the serotonin syndrome during treatment. If serotonin syndrome develops or is suspected during the course of therapy, all serotonergic agents should be discontinued immediately and supportive care rendered as necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5165,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Moderate",
      "effect": "Drugs that are inhibitors of CYP450 2D6 may interfere with the analgesic effect of codeine. The mechanism is decreased in vivo conversion of codeine to morphine, a metabolic reaction mediated by CYP450 2D6.",
      "management_text": "The possibility of reduced or inadequate pain relief should be considered in patients receiving codeine with drugs that inhibit CYP450 2D6. An increase in the codeine dosage or a different analgesic agent may be necessary in patients requiring therapy with CYP450 2D6 inhibitors.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5173,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Isradipine",
      "severity": "Moderate",
      "effect": "Many psychotherapeutic and CNS-active agents (e.g., anxiolytics, sedatives, hypnotics, antidepressants, antipsychotics, opioids, alcohol, muscle relaxants) exhibit hypotensive effects, especially during initiation of therapy and dose escalation. Coadministration with antihypertensives and other hypotensive agents, in particular vasodilators and alpha-blockers, may result in additive effects on blood pressure and orthostasis.",
      "management_text": "Caution and close monitoring for development of hypotension is advised during coadministration of these agents. Avoid alcohol in patients receiving vasodilating antihypertensive drugs. Patients should be advised to avoid rising abruptly from a sitting or recumbent position and to notify their physician if they experience dizziness, lightheadedness, syncope, orthostasis, or tachycardia.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 5205,
      "ingredient1": "codeine"
    },
    {
      "ingredient2": "Sulfasalazine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 243576,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Phenobarbital",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 247968,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Nitroprusside",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 248968,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Phenazopyridine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 249401,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Metoclopramide",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262208,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Nitric Oxide",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262210,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Nitrofurantoin",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262211,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Nitroglycerin",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262212,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Nitrous oxide",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262213,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Phenytoin",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262214,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Primaquine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262215,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Quinine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262217,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Rasburicase",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262218,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Sulfadiazine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262221,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Sulfamethizole",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262222,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Sulfamethoxazole",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262223,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Sulfisoxazole",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262224,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Tafenoquine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262225,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Trimethoprim",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262226,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Prilocaine",
      "severity": "Major",
      "effect": "Prilocaine can cause dose-related methemoglobin formation via its ortho-toluidine metabolite.  Coadministration with other oxidizing agents that can also induce methemoglobinemia including other local anesthetics (e.g., benzocaine, lidocaine),antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Concomitant use of topical lidocaine-prilocaine formulations with other methemoglobin-inducing agents should be avoided in infants younger than 12 months of age.  Caution is advised when used in other patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 290439,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Bupivacaine (liposome)",
      "severity": "Major",
      "effect": "INTERVAL: Administration of bupivacaine liposome suspension together with other local anesthetics, either simultaneously in the same syringe or sequentially to the same site, may impact the pharmacokinetic and/or physicochemical properties of bupivacaine liposome. Additive toxicities may occur when bupivacaine liposome suspension is coadministered with other local anesthetics. The potential for increased risk of systemic toxicities such as methemoglobinemia and central nervous system and cardiovascular adverse reactions should be recognized.",
      "management_text": "Bupivacaine liposome suspension should not be admixed with other, non-bupivacaine based local anesthetics. It may be admixed with bupivacaine hydrochloride as long as the ratio of the milligram dose of bupivacaine HCl to bupivacaine liposome does not exceed 1:2. Additional use of local anesthetics should generally be avoided within 96 hours following administration of bupivacaine liposome suspension. Because the toxic effects of these medications are additive, caution and close observation for development of methemoglobinemia as well as central nervous system and cardiovascular adverse reactions are advised during concomitant use. Early warning signs of central nervous system toxicity may include restlessness, anxiety, incoherent speech, dizziness, lightheadedness, numbness and tingling of the mouth and lips, metallic taste, tinnitus, blurred vision, tremors, twitching, depression, and drowsiness. Cardiovascular toxicity include atrioventricular block, ventricular arrhythmias, cardiac arrest, and decreased cardiac output and arterial blood pressure due to depressed cardiac conductivity, excitability, and myocardial contractility. Patients should have cardiovascular and respiratory vital signs and state of consciousness constantly monitored while under treatment.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 57319,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Dapsone (topical)",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 239768,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Aminosalicylic acid",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 250040,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Amyl Nitrite",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 250381,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Isosorbide dinitrate",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 251661,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Chloroquine",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 252763,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262201,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Flutamide",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262203,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Hydroxyurea",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262204,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262205,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Isosorbide",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262206,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Isosorbide mononitrate",
      "severity": "Major",
      "effect": "Coadministration of local anesthetics with other oxidizing agents that can also induce methemoglobinemia such as antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Close monitoring for signs and symptoms of methemoglobinemia is recommended if local anesthetics must be used with other methemoglobin-inducing agents.  Signs and symptoms of methemoglobinemia may occur immediately or hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia (e.g., cyanotic skin discoloration, abnormal blood coloration, nausea, headache, dizziness, lightheadedness, lethargy, fatigue, dyspnea, tachypnea, tachycardia, palpitation, anxiety, and confusion).  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If a patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 262207,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Tetracaine (ophthalmic)",
      "severity": "Moderate",
      "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).",
      "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 19580,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Moderate",
      "effect": "Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.",
      "management_text": "Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics. ECG monitoring should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 21634,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Benzocaine (topical)",
      "severity": "Moderate",
      "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).",
      "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38094,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Bretylium",
      "severity": "Moderate",
      "effect": "Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.",
      "management_text": "Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics. ECG monitoring should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57317,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57324,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57346,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Quazepam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57410,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Remimazolam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57414,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Tilmanocept",
      "severity": "Moderate",
      "effect": "Locally injected anesthetics have been reported to reduce lymphatic flow of Technetium Tc 99m tilmanocept in animal studies.",
      "management_text": "Co-injection (mixture) of local anesthetics with Technetium Tc 99m tilmanocept is not recommended due to potential impairment of lymph nodal mapping.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57432,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Morphine",
      "severity": "Moderate",
      "effect": "Concomitant epidural administration of local anesthetics may affect the release of morphine sulfate from the liposomal formulation.  The mechanism of interaction is unknown.",
      "management_text": "To minimize the potential for interaction between liposomal morphine and lidocaine-epinephrine test dose (1.5%-1:200,000, 3 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 15 minutes after the test dose before administering the morphine.  Following administration of an analgesic dose of bupivacaine (0.25%, 20 mL), flush the epidural catheter with 1 mL of preservative-free 0.9% normal saline and wait at least 30 minutes before administering the morphine.  Liposomal morphine should not be mixed with any other medications.  Once it has been administered, no other medication should be administered into the epidural space for at least 48 hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 262209,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Silver nitrate (topical)",
      "severity": "Moderate",
      "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 262219,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Silver sulfadiazine (topical)",
      "severity": "Moderate",
      "effect": "Topical nitrate and silver (e.g., cerium nitrate, silver nitrate, silver sulfadiazine) preparations can be systemically absorbed and have been associated with rare reports of methemoglobinemia, primarily in burn patients.  In addition, bacterial conversion of nitrate to nitrite can contribute to methemoglobinemia.  Coadministration with other oxidizing agents that can also induce methemoglobinemia such as ester and amide local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), systemic nitrates and nitrites, sulfonamides, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk.",
      "management_text": "Depending on the circumstances, caution may be advisable when topical nitrate and silver preparations are used concomitantly with other methemoglobin-inducing agents.  Clinicians should be aware of the potential for methemoglobinemia, particularly when treating burn patients.  Signs and symptoms of methemoglobinemia may be delayed some hours after drug exposure.  Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.  In severe cases, patients may progress to central nervous system depression, stupor, seizures, acidosis, cardiac arrhythmias, syncope, shock, coma, and death.  Methemoglobinemia should be considered if central cyanosis is unresponsive to oxygen.  Calculated oxygen saturation and pulse oximetry are generally not accurate in the setting of methemoglobinemia.  The diagnosis can be confirmed by an elevated methemoglobin level of at least 10% using co-oximetry.  Methemoglobin concentrations greater than 10% of total hemoglobin will typically cause cyanosis, and levels over 70% are frequently fatal.  However, symptom severity is not always related to methemoglobin levels.  Mild cases often respond to withdrawal of offending agents and symptomatic support.  If patient does not respond to administration of oxygen, clinically significant or symptomatic methemoglobinemia can be treated with methylene blue 1 to 2 mg/kg by slow intravenous injection over 5 to 10 minutes, which may be repeated within 30 to 60 minutes if necessary.  Higher dosages of methylene blue (usually greater than 7 mg/kg) should be avoided, as it can paradoxically exacerbate methemoglobinemia.  Additionally, methylene blue is ineffective and can cause hemolytic anemia in patients with G6PD deficiency.  These patients may be treated with exchange transfusion, dialysis, and/or hyperbaric oxygenation in addition to symptomatic support.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 262220,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 19265,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Oxybuprocaine (ophthalmic)",
      "severity": "Moderate",
      "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).",
      "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57315,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Chlordiazepoxide",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57320,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Clobazam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57322,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Clorazepic acid",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57325,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57334,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Cinchocaine (topical)",
      "severity": "Moderate",
      "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).",
      "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57335,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Dofetilide",
      "severity": "Moderate",
      "effect": "Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.",
      "management_text": "Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics. ECG monitoring should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57339,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57348,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Halazepam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57352,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Ibutilide",
      "severity": "Moderate",
      "effect": "Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.",
      "management_text": "Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics. ECG monitoring should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57355,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Midazolam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57383,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Oxazepam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57391,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Proparacaine (ophthalmic)",
      "severity": "Moderate",
      "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).",
      "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57407,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Ropivacaine",
      "severity": "Moderate",
      "effect": "The effect of ropivacaine may be additive when used concomitantly with other amide type local anesthetics.",
      "management_text": "Use caution if these drugs are coadministered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57418,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Sotalol",
      "severity": "Moderate",
      "effect": "Amide-type local anesthetics may have additive cardiac effects (e.g., bradycardia, chest pain, heart block, arrhythmias, ECG abnormalities, cardiac arrest) with class III antiarrhythmic agents.",
      "management_text": "Patients treated with class III antiarrhythmic agents (e.g., amiodarone, dofetilide, ibutilide, sotalol) should be under close surveillance during administration of amide-type local anesthetics. ECG monitoring should be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57423,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Temazepam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57425,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Triazolam",
      "severity": "Moderate",
      "effect": "The concomitant use of local anesthetics and benzodiazepines may have additive CNS-depressant effects. Both types of drugs are CNS depressants.",
      "management_text": "Caution is advised during concurrent use. Patients should be monitored for potentially excessive or prolonged CNS depression and other CNS adverse effects. Dosage adjustments may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57434,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Cocaine (topical)",
      "severity": "Moderate",
      "effect": "Some topical anesthetics can be systemically absorbed and cause methemoglobinemia, particularly when applied to mucous membranes. Coadministration with other oxidizing agents that can also induce methemoglobinemia such as injectable local anesthetics, antimalarials (e.g., chloroquine, primaquine, quinine, tafenoquine), nitrates and nitrites, sulfonamides, acetaminophen, aminosalicylic acid, dapsone, dimethyl sulfoxide, flutamide, metoclopramide, nitrofurantoin, phenazopyridine, phenobarbital, phenytoin, and rasburicase may increase the risk. Additional risk factors include very young age (e.g., infants less than 6 months); application to inflamed/abraded areas or broken skin; anemia; cardiac or pulmonary disease; peripheral vascular disease; liver cirrhosis; shock; sepsis; acidosis; and genetic predisposition (e.g., NADH cytochrome-b5 reductase deficiency; glucose-6-phosphate dehydrogenase (G6PD) deficiency; hemoglobin M).",
      "management_text": "Caution is advised when topical anesthetics are used concomitantly with other methemoglobin-inducing agents. Clinicians should be aware of the potential for methemoglobinemia, particularly when topical anesthetics are applied to mucous membranes or given via the oropharyngeal route. Patients or their caregivers should be advised to seek medical attention if they notice signs and symptoms of methemoglobinemia such as slate-grey cyanosis in buccal mucous membranes, lips, and nail beds; nausea; headache; dizziness; lightheadedness; lethargy; fatigue; dyspnea; tachypnea; tachycardia; palpitation; anxiety; and confusion.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 73187,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Hyaluronidase",
      "severity": "Minor",
      "effect": "When hyaluronidase is added to a local anesthetic, the local anesthetic solution undergoes increased absorption, resulting in a shorter duration of action and possible increased frequency of systemic reactions. It may be advisable to monitor the patient for altered anesthetic efficacy and side effects.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 57354,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Alfentanil",
      "severity": "Minor",
      "effect": "Concomitant use of lidocaine theoretically may decrease the clearance and increase the elimination half-life of alfentanil. The mechanism is thought to be inhibition of the cytochrome P-450 isoenzyme 3A3/4. If lidocaine is used in a patient who has been receiving alfentanil for an extended period of time, the patient should be monitored more closely for excessive alfentanil effects (i.e., central nervous system depression, respiratory depression). Other amide-type local anesthetics may interact with alfentanil in a similar manner.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 14361,
      "ingredient1": "mepivacaine"
    },
    {
      "ingredient2": "Dolutegravir",
      "severity": "Major",
      "effect": "INTERVAL: Coadministration with medications containing polyvalent cations such as aluminum, calcium, iron, or magnesium may decrease the oral bioavailability of dolutegravir. The mechanism of interaction has not been established.",
      "management_text": "Dolutegravir should be administered 2 hours before or 6 hours after medications containing polyvalent cations such as antacids, laxatives, or mineral supplements.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 174,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Acalabrutinib",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with drugs that increase gastric pH may significantly decrease the oral bioavailability of acalabrutinib and reduce its concentrations in plasma. The solubility of acalabrutinib is pH-dependent and decreases with increasing pH.",
      "management_text": "Concomitant use of acalabrutinib with proton pump inhibitors should generally be avoided. If acid suppression therapy is required, H2-receptor antagonists or antacids should be considered. The manufacturer recommends taking acalabrutinib 2 hours before H2-receptor antagonists and separating the dosing of antacids by at least 2 hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 2987,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Bisacodyl",
      "severity": "Moderate",
      "effect": "INTERVAL: By increasing gastric pH, antacids may reduce the resistance of the enteric coating of bisacodyl tablets, resulting in earlier release of bisacodyl and gastric irritation and dyspepsia.",
      "management_text": "The administration of antacids and bisacodyl should be separated by at least one hour.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44642,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Bosutinib",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of agents that increase gastric pH such as H2-receptor antagonists or antacids may decrease the oral bioavailability of bosutinib and reduce its concentrations in plasma. The solubility of bosutinib decreases rapidly when the pH is above 5, resulting in reduced absorption.",
      "management_text": "To minimize the potential for interaction, H2-receptor antagonists or antacids should be administered at least 2 hours before or 2 hours after the bosutinib dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 46770,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cefpodoxime",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.",
      "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60319,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ceritinib",
      "severity": "Moderate",
      "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of ceritinib and reduce its bioavailability. The interaction has not been formally studied; however, the solubility of ceritinib has been found to be pH-dependent in vitro and the drug becomes poorly soluble as pH increases.",
      "management_text": "Until more information is available, caution is advised if ceritinib is used with drugs that can alter the gastric pH such as proton pump inhibitors, H2-receptor antagonists, and antacids. The potential for diminished therapeutic effects of ceritinib should be considered, and pharmacologic response should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 61440,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Choline salicylate",
      "severity": "Moderate",
      "effect": "Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7. This interaction is sometimes exploited in the treatment of salicylate toxicity.",
      "management_text": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 64966,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Dabrafenib",
      "severity": "Moderate",
      "effect": "Drugs that alter the pH of the upper gastrointestinal tract may affect the solubility of dabrafenib and reduce its bioavailability. The interaction has not been formally studied with H2-receptor antagonists or antacids; however, the solubility of dabrafenib is known to be pH-dependent. It has been reported to be very slightly soluble at pH 1 and practically insoluble above pH 4 in aqueous media.",
      "management_text": "Until more information is available, caution is advised if dabrafenib is used in combination with H2-receptor antagonists or antacids. The potential for diminished therapeutic effects of dabrafenib should be considered, and pharmacologic response should be closely monitored.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 77831,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Dextroamphetamine",
      "severity": "Moderate",
      "effect": "Alkalinization of the urine can decrease the renal elimination of amphetamines. Amphetamine effects may be prolonged, and the risk of toxicity may be increased.",
      "management_text": "Urinary alkalinizers should generally not be used with amphetamines, particularly in an amphetamine overdose situation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 84738,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Elvitegravir",
      "severity": "Moderate",
      "effect": "INTERVAL: The concomitant use of antacids may significantly decrease the plasma concentrations of elvitegravir. The mechanism of interaction has not been described. In contrast, when the antacid was given 4 hours before or 4 hours after elvitegravir, no significant differences were observed in elvitegravir pharmacokinetics compared to administration of elvitegravir alone.",
      "management_text": "Antacid-containing preparations should be administered at least 2 hours before or 2 hours after the elvitegravir dose. Alternatively, H2-receptor antagonists or proton pump inhibitors may be considered, with no dosage adjustment needed.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 97893,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ferrous fumarate",
      "severity": "Moderate",
      "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.",
      "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105709,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ferrous sulfate anhydrous",
      "severity": "Moderate",
      "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.",
      "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105710,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Iron protein succinylate",
      "severity": "Moderate",
      "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.",
      "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105718,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Thallous Chloride",
      "severity": "Moderate",
      "effect": "Coadministration of certain drugs may alter the myocardial uptake of thallous chloride Tl-201 and interfere with results of myocardial imaging studies. Drugs that increase or decrease coronary blood flow or potassium uptake may alter the biodistribution of thallous chloride Tl-201.",
      "management_text": "Clinicians should be aware of possible diagnostic interference by these drugs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105758,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Tolvaptan",
      "severity": "Moderate",
      "effect": "The use of tolvaptan with other treatments for hyponatremia or medications that increase serum sodium concentration may increase the risk of rapid correction of sodium levels due to additive effects. Other products with high sodium content such as oral sodium, effervescent analgesic preparations,or treatments for dyspepsia may also increase serum sodium concentration.",
      "management_text": "The concomitant use of tolvaptan with hypertonic saline is not recommended. Caution and monitoring are recommended for patients who have received other medications that increase serum sodium levels.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105764,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Velpatasvir",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of velpatasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Velpatasvir exhibits pH-dependent solubility, with increased solubility at lower pH. Drugs that increase gastric pH are expected to decrease the plasma concentration of velpatasvir.",
      "management_text": "If an antacid is required, the antacid should be taken 4 hours before or 4 hours after administration of sofosbuvir-velpatasvir. The same precaution may be applicable to other drugs with antacid effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 112049,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cabotegravir",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with antacids may decrease the bioavailability of oral cabotegravir. The proposed mechanism likely involves a pH-dependent reduction in dissolution and absorption of cabotegravir, which is poorly soluble over a wide pH range. The interaction has not been studied specifically with antacids.",
      "management_text": "To minimize the risk of reduced viral susceptibility and resistance development associated with subtherapeutic levels of cabotegravir, antacids or other medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) should be administered at least 2 hours before or 4 hours after the oral cabotegravir dose.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166557,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Iron",
      "severity": "Moderate",
      "effect": "INTERVAL: The bioavailability of orally administered iron may be reduced by concomitant administration of antacids or other agents with acid-neutralizing effects. The exact mechanism is unknown but may involve reduced iron solubility due to increase in gastric pH and/or reduced absorption due to complexation or precipitation of the iron.",
      "management_text": "To minimize the potential for interaction, it may be appropriate to administer oral iron preparations at least two hours apart from antacids or other agents with acid-neutralizing effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166558,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Doxycycline",
      "severity": "Moderate",
      "effect": "INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.",
      "management_text": "If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 7956,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Amphetamine",
      "severity": "Moderate",
      "effect": "Alkalinization of the urine can decrease the renal elimination of amphetamines. Amphetamine effects may be prolonged, and the risk of toxicity may be increased.",
      "management_text": "Urinary alkalinizers should generally not be used with amphetamines, particularly in an amphetamine overdose situation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 24455,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Acetylsalicylic acid",
      "severity": "Moderate",
      "effect": "Agents that cause urinary alkalinization can reduce serum salicylate concentrations in patients receiving anti-inflammatory dosages of aspirin or other salicylates. The mechanism involves reduction in salicylate renal tubular reabsorption due to increased urinary pH, resulting in increased renal salicylate clearance especially above urine pH of 7. This interaction is sometimes exploited in the treatment of salicylate toxicity.",
      "management_text": "Patients treated chronically with urinary alkalinizers and large doses of salicylates (i.e. 3 g/day or more) should be monitored for potentially diminished or inadequate analgesic and anti-inflammatory effects, and the salicylate dosage adjusted if necessary.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 34008,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Benzphetamine",
      "severity": "Moderate",
      "effect": "Alkalinization of the urine can decrease the renal elimination of amphetamines. Amphetamine effects may be prolonged, and the risk of toxicity may be increased.",
      "management_text": "Urinary alkalinizers should generally not be used with amphetamines, particularly in an amphetamine overdose situation.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 41456,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Tetracycline",
      "severity": "Moderate",
      "effect": "INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.",
      "management_text": "If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44821,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cefditoren",
      "severity": "Moderate",
      "effect": "Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral absorption and plasma concentrations of cefditoren pivoxil.",
      "management_text": "The manufacturer recommends that cefditoren pivoxil not be administered concomitantly with antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60134,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cefuroxime",
      "severity": "Moderate",
      "effect": "INTERVAL: Coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of cefpodoxime proxetil and cefuroxime axetil. The proposed mechanism is a pH-dependent reduction in drug dissolution and absorption.",
      "management_text": "Until further data are available, patients treated with cefpodoxime proxetil or cefuroxime axetil should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) for at least two hours before and after administration of the antibiotic.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 60520,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Chlorpropamide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 63907,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ciprofloxacin",
      "severity": "Moderate",
      "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.",
      "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 66308,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Dasatinib",
      "severity": "Moderate",
      "effect": "INTERVAL: Nonclinical data indicate that the solubility of dasatinib is pH-dependent. Therefore, coadministration with antacids or agents with acid-neutralizing effects may reduce the oral bioavailability of dasatinib.",
      "management_text": "Patients treated with dasatinib should avoid taking antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or paediatric oral solution) for at least two hours before and two hours after administration of dasatinib.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 80427,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Delavirdine",
      "severity": "Moderate",
      "effect": "INTERVAL: Aluminum and magnesium containing antacids have been reported to decrease the bioavailability of delavirdine by an average of 41%. The mechanism may be related to decreased absorption of delavirdine. Other antacids may also interact.",
      "management_text": "Delavirdine administration should be separated by at least 1 hour from one of these preparations.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 82962,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Amprenavir",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of amprenavir and reduce its concentrations in plasma. Amprenavir solubility decreases with increasing pH, thus reduction in gastric acidity may interfere with dissolution of the drug. Subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance. In contrast, the prodrug fosamprenavir appears to be less affected by antacids.",
      "management_text": "Amprenavir should be administered at least 1 hour before or after antacids or other oral preparations containing antacids (e.g., didanosine buffered tablets or pediatric oral solution).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105702,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Demeclocycline",
      "severity": "Moderate",
      "effect": "INTERVAL: Alkalinization of the urine may decrease the plasma concentration of some tetracyclines. The mechanism is not completely understood, but may involve increased renal elimination of tetracyclines when the urine becomes alkalinized.",
      "management_text": "If these drugs must be used together, an alternating dosing schedule is recommended (three to four hours apart).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105704,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ephedrine",
      "severity": "Moderate",
      "effect": "Alkalization of the urine decreases the urinary excretion increases the elimination half-life of ephedrine, pseudoephedrine, and related drugs. Toxicity from long-term use of pseudoephedrine has been demonstrated in patients with persistently alkaline urine.",
      "management_text": "Patients should be monitored for toxic effects such as tremor, anxiety, insomnia, irritability, or nervousness. Dosage reductions may be required.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105707,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Gatifloxacin",
      "severity": "Moderate",
      "effect": "Urinary alkalinizers such as citrates may decrease the solubility of fluoroquinolones in the urine and increase the risk of crystalluria.",
      "management_text": "Concomitant use should generally be avoided. Patients receiving this combination should be monitored for signs of renal toxicity and crystalluria.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105714,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Glipizide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105716,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Glyburide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105717,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Sucralfate",
      "severity": "Moderate",
      "effect": "INTERVAL: Antacid-induced gastric pH changes may reduce binding of sucralfate with the gastrointestinal mucosa resulting in reduced therapeutic efficacy. In addition, aluminum may accumulate in patients with renal failure who are concomitantly taking sucralfate with aluminum-containing antacids.",
      "management_text": "Sucralfate and antacid doses should be separated by at least half an hour.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105756,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Tipranavir",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of tipranavir and reduce its concentrations in plasma. The mechanism of interaction has not been described. The clinical significance of these changes is unknown. However, subtherapeutic antiretroviral drug levels may lead to reduced viral susceptibility and development of resistance.",
      "management_text": "Consideration should be given to separating tipranavir/ritonavir dosing from antacid administration to prevent reduced absorption of tipranavir.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105760,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Tolazamide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105762,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Tolbutamide",
      "severity": "Moderate",
      "effect": "INTERVAL: Some antacids have been reported to increase the rate of absorption and, rarely, the extent of absorption of oral sulfonylureas. The hypoglycemic effects of these agents may be altered.",
      "management_text": "Sulfonylureas should be administered at least two hours before or after antacids when possible. Regular monitoring of blood sugar is advisable. In addition, patients should be apprised of the signs and symptoms of hypoglycemia (e.g., headache, dizziness, drowsiness, nausea, hunger, tremor, weakness, sweating, palpitations), how to treat it, and to contact their physician if it occurs.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 105763,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Itraconazole",
      "severity": "Moderate",
      "effect": "INTERVAL: The dissolution of itraconazole requires an acidic environment. Antacids and some aluminum, calcium, or magnesium containing salts decrease the acidity of the stomach and can reduce the bioavailability and subsequent therapeutic effect of itraconazole.",
      "management_text": "Separation of doses by two or more hours is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 121164,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Erlotinib",
      "severity": "Moderate",
      "effect": "INTERVAL: Concurrent administration of antacids or other agents with acid-neutralizing effects may decrease the oral bioavailability of erlotinib and reduce its concentrations in plasma. The solubility of erlotinib decreases when the pH is over 5, resulting in reduced absorption.",
      "management_text": "If an antacid or other agent with acid-neutralizing effects is required during erlotinib therapy, it should be administered at least 4 hours before or 2 hours after the daily dose of erlotinib.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166559,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Moderate",
      "effect": "INTERVAL: Sodium bicarbonate has been reported to cause widely variable trough plasma levels and reduced blood concentrations of tacrolimus when given close to the time of administration of tacrolimus. No other details were available in the report. Based on in vitro data, the mechanism appears to involve a pH-mediated degradation of tacrolimus. A 75% loss of tacrolimus was observed within 24 hours when tacrolimus was incubated in simulated gastric fluid with sodium bicarbonate. Other antacids tested (aluminum-magnesium hydroxide, magnesium oxide, calcium carbonate) also led to loss of tacrolimus.",
      "management_text": "Until more data are available, it may be prudent to separate the times of administration of tacrolimus and sodium bicarbonate by at least two hours.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 166566,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Digitoxin",
      "severity": "Minor",
      "effect": "Concurrent administration of antacids may decrease the oral bioavailability of digoxin and digitoxin. When digoxin and digitoxin are coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering digoxin or digitoxin at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 105706,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Vismodegib",
      "severity": "Minor",
      "effect": "The solubility of vismodegib is known to be pH-dependent (0.1 mcg/mL at pH 7 and 0.99 mg/mL at pH 1) and drugs that alter the pH of the upper gastrointestinal tract may affects its solubility and reduce its bioavailability.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 105767,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Famotidine",
      "severity": "Minor",
      "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 6741,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Minor",
      "effect": "Antacids and agents with acid-neutralizing effects may impair the absorption of dexamethasone, prednisolone, prednisone, and other corticosteroids, although data from published studies are somewhat conflicting. The mechanism of interaction and clinical significance are unknown. No particular intervention is necessary during concomitant therapy with these agents, but clinicians should be aware of the potential for interaction.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 11422,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Alprazolam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 19393,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Benazepril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 23412,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Minor",
      "effect": "Antacids and agents with acid-neutralizing effects may impair the absorption of dexamethasone, prednisolone, prednisone, and other corticosteroids, although data from published studies are somewhat conflicting. The mechanism of interaction and clinical significance are unknown. No particular intervention is necessary during concomitant therapy with these agents, but clinicians should be aware of the potential for interaction.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 31123,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Minor",
      "effect": "Antacids and agents with acid-neutralizing effects may impair the absorption of dexamethasone, prednisolone, prednisone, and other corticosteroids, although data from published studies are somewhat conflicting. The mechanism of interaction and clinical significance are unknown. No particular intervention is necessary during concomitant therapy with these agents, but clinicians should be aware of the potential for interaction.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 39450,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Betamethasone",
      "severity": "Minor",
      "effect": "Antacids and agents with acid-neutralizing effects may impair the absorption of dexamethasone, prednisolone, prednisone, and other corticosteroids, although data from published studies are somewhat conflicting. The mechanism of interaction and clinical significance are unknown. No particular intervention is necessary during concomitant therapy with these agents, but clinicians should be aware of the potential for interaction.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 42082,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 56066,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Chlordiazepoxide",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 62771,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cimetidine",
      "severity": "Minor",
      "effect": "Antacids and some aluminum, calcium, and magnesium salts may decrease the plasma concentrations of H2-receptor antagonists during oral coadministration. The mechanism of interaction is unknown, but may involve reduced oral absorption due to increased gastric pH. The clinical significance has not been established. As a precaution, patients may consider taking H2-receptor antagonists one to two hours before antacids.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 65769,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Clobazam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 69788,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Clonazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 71278,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Clorazepic acid",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 72042,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Diazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 85480,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Digoxin",
      "severity": "Minor",
      "effect": "Concurrent administration of antacids may decrease the oral bioavailability of digoxin and digitoxin. When digoxin and digitoxin are coadministered with Suprep Bowel Prep (magnesium/potassium/sodium sulfates), the manufacturer recommends administering digoxin or digitoxin at least 2 hours before and not less than 6 hours after Suprep Bowel Prep to avoid chelation with magnesium.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 86831,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Valproic acid",
      "severity": "Minor",
      "effect": "Limited data suggest that concurrent administration of antacids may increase the bioavailability of valproic acid. The mechanism of interaction is unknown. Equivalent doses of antacids containing either aluminum hydroxide-magnesium trisilicate or calcium carbonate also increased the AUC of valproic acid, but the differences were not statistically significant.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 89324,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Duloxetine",
      "severity": "Minor",
      "effect": "Coadministration of enteric-coated duloxetine with substances that raise gastrointestinal pH may result in earlier release of duloxetine from the formulation. The enteric coating is intended to resist drug dissolution until reaching a segment of the gastrointestinal tract where the pH exceeds 5.5. However, coadministration with aluminum- and magnesium-containing antacids (51 mEq) or famotidine has been shown to have no significant effect on the rate or extent of duloxetine absorption following administration of a 40 mg oral dose.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 93894,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Erythromycin",
      "severity": "Minor",
      "effect": "Limited data suggest that concurrent administration of antacids may prolong the elimination half-life of erythromycin. The mechanism of interaction is unknown. These changes are unlikely to be of clinical importance, and no special precautions appear to be necessary.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 95790,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Enalapril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 98772,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Flecainide",
      "severity": "Minor",
      "effect": "Agents that alkalinize the urine decrease the renal elimination of flecainide. The result may be increased plasma flecainide levels and increased effectiveness. The patient should be monitored for flecainide toxicity, and plasma flecainide levels should be checked when appropriate. Also, flecainide effectiveness may be decreased when an agent that alkalinizes the urine is discontinued.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 105711,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Fludrocortisone",
      "severity": "Minor",
      "effect": "Antacids and agents with acid-neutralizing effects may impair the absorption of dexamethasone, prednisolone, prednisone, and other corticosteroids, although data from published studies are somewhat conflicting. The mechanism of interaction and clinical significance are unknown. No particular intervention is necessary during concomitant therapy with these agents, but clinicians should be aware of the potential for interaction.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 105712,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Fosinopril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 105713,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Temazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 105757,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ticlopidine",
      "severity": "Minor",
      "effect": "Coadministration of oral medications that contain magnesium, aluminum, calcium, or sodium (i.e., antacids) has decreased ticlopidine serum concentrations by 18%. Administration of these drugs should be separated by at least three hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 105759,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Trandolapril",
      "severity": "Minor",
      "effect": "Coadministration with antacids may decrease the oral bioavailability of captopril and other angiotensin converting enzyme (ACE) inhibitors due to delayed gastric emptying and/or elevated gastric pH. Based on available data, the clinical significance of this interaction appears to be minor. As a precaution, patients may want to consider separating the administration times of ACE inhibitors and antacids or oral medications that contain antacids (e.g., didanosine buffered tablets or pediatric oral solution) by 1 to 2 hours.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 105765,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Estazolam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 166560,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Flurazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 166562,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Halazepam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 166563,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Triazolam",
      "severity": "Minor",
      "effect": "number of studies have reported that antacids can delay the gastrointestinal absorption and reduce the peak plasma concentration (Cmax) of some benzodiazepines, including clorazepate, chlordiazepoxide and diazepam, although the overall extent of absorption is generally not affected. The exact mechanism of interaction is unknown, but may involve delayed gastric emptying or cation binding of the benzodiazepine.",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Minor",
      "source": "DDInter",
      "ddinter_id": 166567,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Tiotropium",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235387,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Valganciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235388,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Fluticasone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235389,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cefepime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235657,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ursodeoxycholic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235776,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Hydroxychloroquine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235990,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "gamma-Aminobutyric acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236144,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Acetylcysteine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236383,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Vitamin D",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236602,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Galactose",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 236732,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cyclosporine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 194580,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cyanocobalamin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 194834,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Calcitriol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195077,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Folic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195327,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Valsartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 195640,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Fluconazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 196647,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Citalopram",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 197601,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Dapsone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 198479,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Clotrimazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 199020,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Topiramate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 199470,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Bupivacaine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 200350,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Hydromorphone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201388,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 201505,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cetirizine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 202649,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Diltiazem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 202831,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203102,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Amlodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 203636,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Spironolactone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 204755,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Zolpidem",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205061,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Famciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205191,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ceftazidime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 205470,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Celecoxib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 207553,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cefotaxime",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208033,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Haloperidol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208322,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Vancomycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208445,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Aminocaproic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208513,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cyclophosphamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 208879,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Vincristine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209300,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Fluorouracil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209474,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Hydroxyzine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 209854,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210184,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cephalexin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210482,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Clonidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210895,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Valaciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 210972,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211602,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Doxazosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 211801,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Butorphanol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212044,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Testosterone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 212341,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Alendronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213084,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Adenosine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 213319,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Verapamil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214141,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Epinephrine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214327,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Amphotericin B",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214831,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Warfarin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214904,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Tobramycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 214971,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Furosemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 215173,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Dolasetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 216915,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Clopidogrel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217216,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Alprostadil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217654,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Etoposide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 217783,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Acyclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218469,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Gentamicin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 218858,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Fentanyl",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 219379,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Sirolimus",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 220944,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Chlorhexidine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221062,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Isosorbide dinitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221289,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Bumetanide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221554,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Granisetron",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221623,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Didanosine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 221769,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cyclobenzaprine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 222756,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Fexofenadine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 223680,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Dipyridamole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224466,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cytarabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 224696,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Gabapentin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225143,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Doxorubicin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225349,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225533,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ganciclovir",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 225930,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Felodipine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226665,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Irbesartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226872,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Tolterodine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 226975,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227226,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Thalidomide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227267,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 227834,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Amoxicillin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228092,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Fludarabine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 228741,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Heparin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 229944,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 230481,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Carvedilol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231044,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 231609,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ifosfamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232006,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Clindamycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232326,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Zopiclone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 232782,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ceftriaxone",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233313,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Finasteride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233594,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 233980,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Docetaxel",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 234984,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cefazolin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235273,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Bortezomib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235348,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Torasemide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235349,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Eletriptan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235350,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Gadodiamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235351,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Etomidate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235353,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Gefitinib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235354,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Sorafenib",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235355,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Zoledronic acid",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235356,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Allopurinol",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235359,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cisplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235361,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Gadoversetamide",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235362,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cisatracurium",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235363,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Voriconazole",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235364,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Simvastatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235365,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Tamsulosin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235368,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Sufentanil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235369,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Sulfasalazine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235371,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Alfentanil",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235372,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Dobutamine",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235373,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235375,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Telmisartan",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235376,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Ezetimibe",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235377,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Cinacalcet",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235378,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Isosorbide mononitrate",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235379,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Calcium chloride",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235382,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Clarithromycin",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235383,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Aminophylline",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235384,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Vecuronium",
      "severity": "Unknown",
      "effect": "None",
      "management_text": "-",
      "mechanism_text": null,
      "risk_level": "Unknown",
      "source": "DDInter",
      "ddinter_id": 235386,
      "ingredient1": "Sodium bicarbonate"
    },
    {
      "ingredient2": "Rabeprazole",
      "severity": "Major",
      "effect": "Coadministration with proton pump inhibitors (PPIs) may increase the serum concentrations of methotrexate (MTX) and its potentially active 7-hydroxy metabolite. The proposed mechanism is PPI inhibition of the active tubular secretion of MTX and 7-hydroxymethotrexate via renal H+/K+ ATPase pumps. Inhibition of the breast cancer resistance protein (BCRP)-mediated transport of methotrexate and 7-hydroxymethotrexate by the proton pump inhibitors has also been suggested.",
      "management_text": "Proton pump inhibitor therapy should preferably be stopped several days prior to administration of methotrexate. In addition, it is not generally recommended to use proton pump inhibitors with high-dose methotrexate therapy, particularly in the presence of renal impairment. If concomitant use is necessary, clinicians should consider the potential for interaction and closely monitor methotrexate serum levels and toxicity. Use of an H2 antagonist may also be an appropriate alternative. It is not known if the interaction occurs with low, oral doses of methotrexate used to treat rheumatoid arthritis.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 6984,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Ibuprofen",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 10331,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Amoxicillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 24287,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Acetylsalicylic acid",
      "severity": "Major",
      "effect": "Salicylates may interfere with the renal elimination of methotrexate and may displace it from binding sites. The pharmacologic effect and toxicity of methotrexate may be increased. Patients receiving high-dose methotrexate are at a greater risk of developing toxicity.",
      "management_text": "If these agents must be used concomitantly, caution should be exercised and the patient should be monitored closely for signs and symptoms of bone marrow suppression and nephrotoxicity. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician. Patients should also be counseled to avoid any other over-the-counter salicylate products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 33935,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Baricitinib",
      "severity": "Major",
      "effect": "Coadministration of baricitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. The most common serious infections with baricitinib treatment include pneumonia, herpes zoster, and urinary tract infection. Opportunistic infections include tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus. Lymphoma and other malignancies have also been observed with baricitinib use, with or without concomitant immunosuppressants.",
      "management_text": "Close monitoring for the development of infection is recommended if baricitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and baricitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, baricitinib should be interrupted until the infection is controlled.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 38810,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Human botulinum neurotoxin A/B immune globulin",
      "severity": "Major",
      "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.",
      "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 46866,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Diclofenac",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 54051,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Certolizumab pegol",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 61672,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Choline salicylate",
      "severity": "Major",
      "effect": "Salicylates may interfere with the renal elimination of methotrexate and may displace it from binding sites. The pharmacologic effect and toxicity of methotrexate may be increased. Patients receiving high-dose methotrexate are at a greater risk of developing toxicity.",
      "management_text": "If these agents must be used concomitantly, caution should be exercised and the patient should be monitored closely for signs and symptoms of bone marrow suppression and nephrotoxicity. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician. Patients should also be counseled to avoid any other over-the-counter salicylate products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 64929,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Iothalamic acid",
      "severity": "Major",
      "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.",
      "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 74582,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Human cytomegalovirus immune globulin",
      "severity": "Major",
      "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.",
      "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 77475,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Oxaprozin",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81205,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Deferasirox",
      "severity": "Major",
      "effect": "Theoretical concerns exist regarding the potential for increased risk of renal impairment during coadministration of deferasirox with other nephrotoxic agents. The use of deferasirox has been associated with postmarketing reports of acute renal failure, in some cases resulting in dialysis or even fatality.",
      "management_text": "Caution is advised if deferasirox is used in combination with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Serum creatinine and/or creatinine clearance should be closely monitored (e.g., prior to initiation of deferasirox therapy, then weekly during the first month after initiation or modification of therapy and monthly thereafter), especially in the elderly and patients with preexisting renal impairment, comorbid conditions, dehydration, or severe infections. Dosage reduction, interruption, or discontinuation should be considered in the presence of creatinine elevations. A progressive increase in serum creatinine beyond the age-appropriate upper limit of normal may warrant an interruption of therapy. Once the creatinine has returned to within the normal range, therapy may be reinitiated at a lower dose followed by a gradual dose escalation according to the product labeling, provided the clinical benefit is expected to outweigh potential risks.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81589,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Deferiprone",
      "severity": "Major",
      "effect": "Coadministration of deferiprone and other drugs that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity. Deferiprone alone can cause agranulocytosis, which may be preceded by neutropenia.",
      "management_text": "Concomitant use of deferiprone with other drugs known to be associated with neutropenia or agranulocytosis should generally be avoided. Otherwise, close monitoring of absolute neutrophil count (ANC) is recommended if coadministration is required.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 81879,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Dexlansoprazole",
      "severity": "Major",
      "effect": "Coadministration with proton pump inhibitors (PPIs) may increase the serum concentrations of methotrexate (MTX) and its potentially active 7-hydroxy metabolite. The proposed mechanism is PPI inhibition of the active tubular secretion of MTX and 7-hydroxymethotrexate via renal H+/K+ ATPase pumps. Inhibition of the breast cancer resistance protein (BCRP)-mediated transport of methotrexate and 7-hydroxymethotrexate by the proton pump inhibitors has also been suggested.",
      "management_text": "Proton pump inhibitor therapy should preferably be stopped several days prior to administration of methotrexate. In addition, it is not generally recommended to use proton pump inhibitors with high-dose methotrexate therapy, particularly in the presence of renal impairment. If concomitant use is necessary, clinicians should consider the potential for interaction and closely monitor methotrexate serum levels and toxicity. Use of an H2 antagonist may also be an appropriate alternative. It is not known if the interaction occurs with low, oral doses of methotrexate used to treat rheumatoid arthritis.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 84788,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Naproxen",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 103213,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Aminolevulinic acid",
      "severity": "Major",
      "effect": "Patients exposed to photosensitizing agents may be at increased risk of a phototoxic skin reaction (severe sunburn) during use of aminolevulinic acid.",
      "management_text": "Photosensitizing agents (e.g., fluoroquinolones, phenothiazines, retinoids, sulfonamides, sulfonylureas, tetracyclines, thiazide diuretics, griseofulvin, St. John's wort) and topical preparations containing aminolevulinic acid should generally not be administered for 24 hours before and after oral administration of aminolevulinic acid.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106024,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Bacampicillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106027,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Bacillus calmette-guerin substrain tice live antigen",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106028,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Bismuth subsalicylate",
      "severity": "Major",
      "effect": "Salicylates may interfere with the renal elimination of methotrexate and may displace it from binding sites. The pharmacologic effect and toxicity of methotrexate may be increased. Patients receiving high-dose methotrexate are at a greater risk of developing toxicity.",
      "management_text": "If these agents must be used concomitantly, caution should be exercised and the patient should be monitored closely for signs and symptoms of bone marrow suppression and nephrotoxicity. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician. Patients should also be counseled to avoid any other over-the-counter salicylate products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106033,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Bromfenac",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106034,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Carbenicillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106036,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Cloxacillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106044,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Diflunisal",
      "severity": "Major",
      "effect": "Salicylates may interfere with the renal elimination of methotrexate and may displace it from binding sites. The pharmacologic effect and toxicity of methotrexate may be increased. Patients receiving high-dose methotrexate are at a greater risk of developing toxicity.",
      "management_text": "If these agents must be used concomitantly, caution should be exercised and the patient should be monitored closely for signs and symptoms of bone marrow suppression and nephrotoxicity. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician. Patients should also be counseled to avoid any other over-the-counter salicylate products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106051,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Esomeprazole",
      "severity": "Major",
      "effect": "Coadministration with proton pump inhibitors (PPIs) may increase the serum concentrations of methotrexate (MTX) and its potentially active 7-hydroxy metabolite. The proposed mechanism is PPI inhibition of the active tubular secretion of MTX and 7-hydroxymethotrexate via renal H+/K+ ATPase pumps. Inhibition of the breast cancer resistance protein (BCRP)-mediated transport of methotrexate and 7-hydroxymethotrexate by the proton pump inhibitors has also been suggested.",
      "management_text": "Proton pump inhibitor therapy should preferably be stopped several days prior to administration of methotrexate. In addition, it is not generally recommended to use proton pump inhibitors with high-dose methotrexate therapy, particularly in the presence of renal impairment. If concomitant use is necessary, clinicians should consider the potential for interaction and closely monitor methotrexate serum levels and toxicity. Use of an H2 antagonist may also be an appropriate alternative. It is not known if the interaction occurs with low, oral doses of methotrexate used to treat rheumatoid arthritis.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106060,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Etodolac",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106066,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Everolimus",
      "severity": "Major",
      "effect": "Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive adverse effects on the kidney. Clinical experience in coadministration with cyclosporine indicates increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. An interaction with ibuprofen resulting in acute renal failure was suspected in two liver transplant patients who had been stabilized on tacrolimus.",
      "management_text": "Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; cyclosporine; deferasirox; gallium nitrate; lithium; mesalamine; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be closely monitored both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106068,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Fenoprofen",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106074,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Fingolimod",
      "severity": "Major",
      "effect": "Coadministration of fingolimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of infections. Fingolimod causes reversible sequestration of lymphocytes in lymphoid tissues.",
      "management_text": "The safety and efficacy of fingolimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration. A complete blood count is recommended prior to starting fingolimod if a recent one (i.e., within last 6 months) is not available.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106076,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Flurbiprofen",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106083,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Golimumab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106102,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Inotersen",
      "severity": "Major",
      "effect": "Coadministration of inotersen with other nephrotoxic agents may increase the risk of renal impairment due to additive adverse effects on the kidney. Inotersen can cause glomerulonephritis that may result in dialysis-dependent renal failure.",
      "management_text": "Caution is advised when inotersen is prescribed with nephrotoxic drugs and other drugs that may impair renal function (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, cidofovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, cisplatin, clofarabine, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravascular contrast media; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) . Serum creatinine, estimated glomerular filtration rate (eGFR), urine protein to creatinine ratio (UPCR), and a urinalysis should be obtained prior to initiation of inotersen and regularly during and for at least 8 weeks after treatment in accordance with the product labeling. Inotersen should generally not be initiated in patients with a UPCR of 1000 mg/g or higher, or in patients who are unable to adhere to the recommended laboratory monitoring and management guidelines. Patients or their caregivers should be apprised of the signs and symptoms of glomerulonephritis and to seek medical attention if they occur, including edema, shortness of breath, coughing, hematuria, and decreased urination.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106121,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Iodipamide",
      "severity": "Major",
      "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.",
      "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106130,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Iodixanol",
      "severity": "Major",
      "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.",
      "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106131,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Iohexol",
      "severity": "Major",
      "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.",
      "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106132,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Iopamidol",
      "severity": "Major",
      "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.",
      "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106133,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Iopromide",
      "severity": "Major",
      "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.",
      "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106134,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Ioversol",
      "severity": "Major",
      "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.",
      "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106135,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Ioxilan",
      "severity": "Major",
      "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.",
      "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106136,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Mezlocillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106185,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Mipomersen",
      "severity": "Major",
      "effect": "Coadministration of mipomersen with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Mipomersen can cause elevations in serum transaminases and hepatic steatosis.",
      "management_text": "Caution is advised if mipomersen is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; amiodarone; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; kinase inhibitors; methotrexate; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; tamoxifen; tetracyclines; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; other lipid-lowering medications such as fenofibrate, lomitapide, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Mipomersen has not been studied with other LDL-lowering agents that can also increase hepatic fat, thus concomitant use is not recommended. Patients treated with mipomersen should have serum ALT, AST, alkaline phosphatase, and total bilirubin measured prior to initiation of treatment and regularly during treatment in accordance with the product labeling, and the dosing adjusted or interrupted as necessary. Since alcohol may increase levels of hepatic fat and induce or exacerbate liver injury, the manufacturer recommends that patients taking mipomersen not consume more than one alcoholic drink per day. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106188,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Mumps virus strain B level jeryl lynn live antigen",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106194,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Nafcillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106196,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Nitrous oxide",
      "severity": "Major",
      "effect": "The use of nitrous oxide anesthesia may increase the risk of methotrexate-associated cytotoxicity. The proposed mechanism is that nitrous oxide increases the effects of methotrexate on tetrahydrofolate metabolism, resulting in greater toxicity.",
      "management_text": "The concomitant use of nitrous oxide anesthesia with methotrexate should be avoided. Some authorities consider the use of nitrous oxide with methotrexate to be contraindicated (CA). If concomitant use is unavoidable, patients should be closely monitored for toxicity during the postoperative period. Intravenous hydration and calcium folinate (leucovorin) are recommended to decrease the incidence of methotrexate toxicity.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106212,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Oxacillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106221,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Ozanimod",
      "severity": "Major",
      "effect": "Coadministration of ozanimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Ozanimod causes reversible sequestration of lymphocytes in lymphoid tissues. The safety and efficacy of ozanimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated.",
      "management_text": "Concomitant use of ozanimod with antineoplastic, immunosuppressive, or immune-modulating agents should be avoided according to some authorities (UK); however, other authorities (AU, US) advise caution and close monitoring during coadministration and for up to 3 months after the last dose of ozanimod. When switching from drugs with prolonged immune effects to ozanimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106226,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Benzylpenicillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106241,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Pexidartinib",
      "severity": "Major",
      "effect": "Serious cases of hepatotoxicity, some fatal, have occurred in patients treated with pexidartinib. Concomitant use of other potentially hepatotoxic agents may potentiate the risk of liver injury. The mechanism of hepatotoxicity is unknown, its occurrence cannot be predicted, and it is unknown whether liver injury occurs in the absence of increased transaminases.",
      "management_text": "The use of pexidartinib with other potentially hepatotoxic agents should be avoided. Patients treated with pexidartinib should have liver function tests, including AST, ALT, total bilirubin, direct bilirubin, ALP, and gamma-glutamyl transferase (GGT), prior to initiation of pexidartinib, weekly for the first 8 weeks, every 2 weeks for the next month, and every 3 months thereafter. Pexidartinib therapy may require a dosage reduction, to be withheld, or permanently discontinued based on the severity of the hepatotoxicity. A recurrence of increased serum transaminases, bilirubin, or ALP may occur upon rechallenge with a reduced dose of pexidartinib. Liver function tests should be performed weekly for the first month after rechallenge. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106246,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Phenylbutazone",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106247,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Probenecid",
      "severity": "Major",
      "effect": "Probenecid inhibits the renal elimination of methotrexate. The pharmacologic effect and toxicity of methotrexate may be increased, especially in patients receiving high-dose methotrexate.",
      "management_text": "If this combination must be used, a reduction in methotrexate dosage may be needed and the patient should be closely monitored for signs and symptoms of bone marrow suppression, hepatotoxicity, and nephrotoxicity. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, malaise, shortness of breath, lower extremity edema, jaundice, or change in stool or urine color to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106266,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Human Rho(D) immune globulin",
      "severity": "Major",
      "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.",
      "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106276,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Rotavirus vaccine",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106287,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Rubella virus vaccine",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106288,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Salsalate",
      "severity": "Major",
      "effect": "Salicylates may interfere with the renal elimination of methotrexate and may displace it from binding sites. The pharmacologic effect and toxicity of methotrexate may be increased. Patients receiving high-dose methotrexate are at a greater risk of developing toxicity.",
      "management_text": "If these agents must be used concomitantly, caution should be exercised and the patient should be monitored closely for signs and symptoms of bone marrow suppression and nephrotoxicity. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician. Patients should also be counseled to avoid any other over-the-counter salicylate products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106292,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Samarium (153Sm) lexidronam",
      "severity": "Major",
      "effect": "Theoretical concerns exist that chemotherapeutic agents and other bone marrow depressants may potentiate the myelosuppressive effects of samarium sm 153 lexidronam.",
      "management_text": "The manufacturer recommends avoiding concomitant use of samarium sm 153 lexidronam with chemotherapy or external beam radiation therapy unless benefits are anticipated to outweigh the risks. Moreover, samarium sm 153 lexidronam should not be given after either of these treatments until there has been time for adequate marrow recovery. Caution and close monitoring of bone marrow function are advisable if coadministration with other myelotoxic agents is required. Patients should be advised to contact their physician if they develop signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, unusual bleeding or bruising, or signs of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106293,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Siponimod",
      "severity": "Major",
      "effect": "Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects.",
      "management_text": "The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106301,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Sirolimus",
      "severity": "Major",
      "effect": "Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive adverse effects on the kidney. Clinical experience in coadministration with cyclosporine indicates increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. An interaction with ibuprofen resulting in acute renal failure was suspected in two liver transplant patients who had been stabilized on tacrolimus.",
      "management_text": "Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; cyclosporine; deferasirox; gallium nitrate; lithium; mesalamine; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be closely monitored both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106303,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Smallpox (Vaccinia) Vaccine, Live",
      "severity": "Major",
      "effect": "The administration of live smallpox virus vaccine during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Routine, nonemergency smallpox vaccination is contraindicated in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued for at least 3 months in most cases. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide).",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106304,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Salicylic acid (sodium)",
      "severity": "Major",
      "effect": "Salicylates may interfere with the renal elimination of methotrexate and may displace it from binding sites. The pharmacologic effect and toxicity of methotrexate may be increased. Patients receiving high-dose methotrexate are at a greater risk of developing toxicity.",
      "management_text": "If these agents must be used concomitantly, caution should be exercised and the patient should be monitored closely for signs and symptoms of bone marrow suppression and nephrotoxicity. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician. Patients should also be counseled to avoid any other over-the-counter salicylate products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106309,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Sulindac",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106322,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Tacrolimus",
      "severity": "Major",
      "effect": "Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive adverse effects on the kidney. Clinical experience in coadministration with cyclosporine indicates increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. An interaction with ibuprofen resulting in acute renal failure was suspected in two liver transplant patients who had been stabilized on tacrolimus.",
      "management_text": "Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; cyclosporine; deferasirox; gallium nitrate; lithium; mesalamine; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be closely monitored both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106325,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Talimogene laherparepvec",
      "severity": "Major",
      "effect": "Talimogene laherparepvec is a live, attenuated herpes simplex virus. Administration during immunosuppressant or intense antineoplastic therapy may be associated with a risk of potentially life-threatening disseminated herpetic infection due to enhanced virus replication in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "Talimogene laherparepvec should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Treatment with talimogene laherparepvec may need to be deferred until after such therapy is discontinued and the patient's immune system has sufficiently recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106327,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Temsirolimus",
      "severity": "Major",
      "effect": "Coadministration of macrolide immunosuppressants with other nephrotoxic agents may increase the risk and/or severity of renal impairment due to additive adverse effects on the kidney. Clinical experience in coadministration with cyclosporine indicates increased renal toxicity as evidenced by increased serum creatinine and decreased glomerular filtration rate. An interaction with ibuprofen resulting in acute renal failure was suspected in two liver transplant patients who had been stabilized on tacrolimus.",
      "management_text": "Caution is advised when macrolide immunosuppressants is used in patients who have recently received or are receiving treatment with other potentially nephrotoxic drugs (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; cyclosporine; deferasirox; gallium nitrate; lithium; mesalamine; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be closely monitored both during and after discontinuation of therapy. Patients should be advised to seek medical attention if they experience symptoms that may indicate nephrotoxicity such as decreased urine output, sudden weight gain, fluid retention, edema, or shortness of breath.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106333,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Teriflunomide",
      "severity": "Major",
      "effect": "Coadministration of methotrexate and leflunomide has been associated with an increased risk for hepatotoxicity. The risk probably extends to teriflunomide, its principal active metabolite, because recommended dosages of both result in a similar range of plasma concentrations of teriflunomide.",
      "management_text": "The use of leflunomide or teriflunomide in combination with methotrexate is not recommended. Since the active metabolite of leflunomide may remain in the body for up to 2 years, the cholestyramine washout procedure is recommended when changing from leflunomide to methotrexate. Liver enzyme levels should be obtained before beginning leflunomide/teriflunomide and monthly during therapy. If ALT increases to 2 to 3 times normal, the dose should be reduced and liver enzymes monitored weekly. If ALT increases to more than 3 times normal, therapy should be discontinued and the washout procedure should be instituted.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106335,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Thalidomide",
      "severity": "Major",
      "effect": "Coadministration of thalidomide with glucocorticoids and/or antineoplastic agents in the treatment of malignancy may potentiate the risk of thromboembolism. The exact mechanism is unknown but likely multifactorial.",
      "management_text": "Close monitoring for DVT or pulmonary embolism is recommended in patients who require thalidomide therapy in combination with glucocorticoids and/or cytotoxic agents. Patients should be advised to seek medical attention if they develop potential signs and symptoms of thromboembolism such as chest pain, shortness of breath, and pain or swelling in the arms or legs. Prophylaxis with anticoagulants such as low-molecular weight heparins or warfarin may be appropriate, but the decision to take thromboprophylactic measures should be made after careful assessment of underlying risk factors. If a thromboembolic event occurs during therapy with thalidomide, treatment must be discontinued and standard anticoagulation therapy started. Once anticoagulation is stabilized and complications of the thromboembolic event under control, thalidomide may be restarted at the original dose if benefit is deemed to outweigh the risks.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106337,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Ticarcillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106340,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Tofacitinib",
      "severity": "Major",
      "effect": "Coadministration of tofacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies. Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients receiving tofacitinib, most of whom were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Lymphoma and other malignancies have also been observed with tofacitinib use, with or without concomitant immunosuppressants.",
      "management_text": "Close monitoring for the development of infection is recommended if tofacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and tofacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. If a serious infection, an opportunistic infection, or sepsis develops, tofacitinib should be interrupted until the infection is controlled.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106344,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Typhoid vaccine (live)",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106363,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Upadacitinib",
      "severity": "Major",
      "effect": "Coadministration of upadacitinib with other immuno- or myelosuppressive agents may potentiate the risk of infections as well as lymphoma and other malignancies.",
      "management_text": "Close monitoring for the development of infection is recommended if upadacitinib is used in combination with other immuno- or myelosuppressive agents, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. Lymphocyte and neutrophil counts as well as hemoglobin should be evaluated at baseline and regularly during therapy, and upadacitinib dosage adjusted as necessary in accordance with the product labeling. Patients should be advised to contact their physician if they develop signs or symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, or pain or burning during urination. If a serious or opportunistic infection develops, upadacitinib should be interrupted until the infection is controlled.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106364,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Varicella Zoster Vaccine (Recombinant)",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106370,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Yellow Fever Vaccine",
      "severity": "Major",
      "effect": "The administration of live, attenuated viral or bacterial vaccines during immunosuppressant or intense antineoplastic therapy may be associated with a risk of disseminated infection due to enhanced replication of vaccine virus or bacteria in the presence of diminished immune competence. Patients may be immunosuppressed if they have recently received or are receiving alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids. These patients may also have increased adverse reactions and decreased or suboptimal immunologic response to vaccines.",
      "management_text": "In general, live attenuated vaccines should not be used in patients receiving immunosuppressive therapy or cancer chemotherapy. Vaccination should be deferred until after such therapy is discontinued and immune function has been restored, usually 4 to 12 weeks after stopping immunosuppressive therapy. A longer waiting period may be necessary following treatment with agents that have a prolonged elimination half-life (e.g., leflunomide, teriflunomide). Current local immunization guidelines should be consulted for recommendations.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106380,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Acitretin",
      "severity": "Major",
      "effect": "The use of etretinate (of which acitretin is the active metabolite) in combination with methotrexate has been associated with an increased risk of hepatitis. The exact mechanism of interaction is unknown but does not appear to be pharmacokinetically related. These agents individually have been associated with the development of hepatotoxicity and may have additive effects during coadministration.",
      "management_text": "The use of acitretin in combination with methotrexate is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 7064,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Adalimumab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 9280,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Ampicillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 24646,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Human immunoglobulin G (intravenous)",
      "severity": "Major",
      "effect": "Coadministration of intravenous immune globulin preparations with nephrotoxic agents may potentiate the risk of renal impairment. Many commercially available intravenous formulations of immune globulin contain sucrose as a stabilizer.",
      "management_text": "Intravenous immune globulin preparations should be administered cautiously in patients treated with other potentially nephrotoxic agents (e.g., e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Clinicians should ensure that patients are not volume depleted prior to the initiation of immune globulin therapy. Monitoring of urine output and renal function tests, including the measurement of blood urea nitrogen (BUN) and serum creatinine, is recommended prior to the initial infusion and at appropriate intervals thereafter.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 32544,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Cidofovir",
      "severity": "Major",
      "effect": "Coadministration of cidofovir with other nephrotoxic agents may increase the risk of renal impairment due to additive effects on the kidney. Dose-related nephrotoxicity is the major toxicity of cidofovir. Cases of acute renal failure resulting in dialysis and/or contributing to death have occurred with as few as one or two doses of cidofovir.",
      "management_text": "Concomitant use of cidofovir with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; aminosalicylates; antiviral/antiretroviral agents such as acyclovir, adefovir, foscarnet, ganciclovir, and tenofovir; antineoplastics such as aldesleukin, cisplatin, clofarabine, ifosfamide, streptozocin, and high intravenous dosages of methotrexate; chelating agents such as deferasirox, deferoxamine, edetate disodium, and edetate calcium disodium; immunosuppressants such as cyclosporine, everolimus, sirolimus, and tacrolimus; intravascular contrast media; intravenous bisphosphonates; intravenous pentamidine; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents; gallium nitrate; lithium; penicillamine) is considered contraindicated.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 65108,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Cladribine",
      "severity": "Major",
      "effect": "The use of cladribine with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Cladribine alone may cause severe and prolonged myelosuppression, lymphopenia, and opportunistic infections. The risk may theoretically increase when coadministered with other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids.",
      "management_text": "Concomitant use of oral cladribine with immunosuppressive or myelosuppressive agents should be avoided if possible. Acute short-term therapy with corticosteroids can be administered. Caution is advised if IV cladribine must be used in patients who have recently received or are receiving treatment with other immunosuppressive or myelosuppressive drugs, and vice versa. Close clinical and laboratory monitoring for the development of severe hematologic adverse effects is recommended both during and after discontinuation of therapy. In patients who have previously been treated with immunomodulatory or immunosuppressive drugs, consider potential additive effect, mode of action, and duration of effect of the other drugs prior to initiation of cladribine. Patients should be advised to contact their physician if they develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 67546,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Clozapine",
      "severity": "Major",
      "effect": "Coadministration of clozapine with other agents that can cause neutropenia or agranulocytosis may increase the risk and/or severity of hematologic toxicity.",
      "management_text": "Caution and close monitoring are advised when clozapine is used with other agents that have a well-known potential to cause agranulocytosis or otherwise suppress bone marrow function. Agents that may be significantly myelotoxic include antineoplastic drugs, some anticonvulsant and antirheumatic medications, albendazole, chloramphenicol, colchicine, dapsone, interferons, linezolid, pentamidine, procainamide, and zidovudine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 72417,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Diatrizoate",
      "severity": "Major",
      "effect": "Concomitant use of intravascular radiocontrast media with other nephrotoxic agents may potentiate the risk of contrast-induced nephropathy and renal impairment. While the condition is usually transient and asymptomatic, it can be associated with increased risk of renal failure, dialysis, prolonged hospitalization, significant long-term morbidity, and mortality.",
      "management_text": "Alternative imaging techniques that do not require contrast should be considered in patients who are at increased risk for contrast-induced nephropathy. Any repeat procedures with contrast media, if necessary, should not occur until at least 48 to 72 hours after the previous contrast exposure and renal function has fully recovered.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 77392,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Omeprazole",
      "severity": "Major",
      "effect": "Coadministration with proton pump inhibitors (PPIs) may increase the serum concentrations of methotrexate (MTX) and its potentially active 7-hydroxy metabolite. The proposed mechanism is PPI inhibition of the active tubular secretion of MTX and 7-hydroxymethotrexate via renal H+/K+ ATPase pumps. Inhibition of the breast cancer resistance protein (BCRP)-mediated transport of methotrexate and 7-hydroxymethotrexate by the proton pump inhibitors has also been suggested.",
      "management_text": "Proton pump inhibitor therapy should preferably be stopped several days prior to administration of methotrexate. In addition, it is not generally recommended to use proton pump inhibitors with high-dose methotrexate therapy, particularly in the presence of renal impairment. If concomitant use is necessary, clinicians should consider the potential for interaction and closely monitor methotrexate serum levels and toxicity. Use of an H2 antagonist may also be an appropriate alternative. It is not known if the interaction occurs with low, oral doses of methotrexate used to treat rheumatoid arthritis.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 105727,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Dicloxacillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106050,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Etanercept",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106061,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Indomethacin",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106117,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Infliximab",
      "severity": "Major",
      "effect": "The use of tumor necrosis factor (TNF) blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Serious infections and sepsis, including fatalities, have been reported with the use of TNF blockers, particularly in patients on concomitant immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, and long-term topical or inhaled corticosteroids. Concomitant use of TNF blockers with other immunosuppressants such as azathioprine or mercaptopurine may also increase the risk of a rare and often fatal cancer of white blood cells known as hepatosplenic T-Cell lymphoma (HSTCL).",
      "management_text": "Patients receiving a TNF blocker alone or with other immunosuppressive or myelosuppressive agents should be monitored closely for the development of infections. TNF blocker therapy should be discontinued if a serious infection or sepsis occurs. Close monitoring for signs and symptoms of HSTCL (e.g., splenomegaly, hepatomegaly, abdominal pain, persistent fever, night sweats, weight loss) is also recommended during use of TNF blockers, particularly in combination with other immunosuppressants such as azathioprine and mercaptopurine.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106118,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Nabumetone",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106195,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Natalizumab",
      "severity": "Major",
      "effect": "Concomitant or recent use of immunosuppressant, immunomodulating, or antineoplastic agents in patients treated with natalizumab may increase the risk of infections including progressive multifocal leukoencephalopathy (PML), a severely disabling, potentially fatal opportunistic viral infection of the brain.",
      "management_text": "The safety and efficacy of natalizumab in combination with immunosuppressant, immunomodulating, antineoplastic or other myelosuppressive agents have not been established. In general, patients receiving chronic therapy with such agents should not be treated with natalizumab due to potentially increased risk of PML and other serious infections. Typical symptoms associated with PML are diverse, progress over days to weeks, and include progressive weakness on one side of the body, clumsiness of limbs, disturbance of vision, and changes in thinking, memory, and orientation leading to confusion and personality changes. Due to the long half-life of natalizumab, immune effects are possible for up to 2 to 3 months following its discontinuation.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106199,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Pantoprazole",
      "severity": "Major",
      "effect": "Coadministration with proton pump inhibitors (PPIs) may increase the serum concentrations of methotrexate (MTX) and its potentially active 7-hydroxy metabolite. The proposed mechanism is PPI inhibition of the active tubular secretion of MTX and 7-hydroxymethotrexate via renal H+/K+ ATPase pumps. Inhibition of the breast cancer resistance protein (BCRP)-mediated transport of methotrexate and 7-hydroxymethotrexate by the proton pump inhibitors has also been suggested.",
      "management_text": "Proton pump inhibitor therapy should preferably be stopped several days prior to administration of methotrexate. In addition, it is not generally recommended to use proton pump inhibitors with high-dose methotrexate therapy, particularly in the presence of renal impairment. If concomitant use is necessary, clinicians should consider the potential for interaction and closely monitor methotrexate serum levels and toxicity. Use of an H2 antagonist may also be an appropriate alternative. It is not known if the interaction occurs with low, oral doses of methotrexate used to treat rheumatoid arthritis.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106230,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Phenoxymethylpenicillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106244,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Piperacillin",
      "severity": "Major",
      "effect": "Concomitant use of large doses of penicillins may elevate serum methotrexate concentrations. The mechanism may involve competitive inhibition of renal tubular secretion of methotrexate.",
      "management_text": "If a penicillin must be used concurrently, close monitoring of methotrexate serum concentrations and of the patient for evidence of serious methotrexate toxicity are recommended. Leucovorin rescue should be available. Methotrexate dose reductions may be necessary. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, use of other antimicrobials may be preferable. Patients should be advised to promptly report symptoms including fever, chills, sore throat, bruising, bleeding, stomatitis, or malaise to their physician.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106249,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Piroxicam",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106251,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Tolmetin",
      "severity": "Major",
      "effect": "Coadministration with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the plasma concentrations and toxicities of methotrexate. The proposed mechanism is NSAID inhibition of the renal elimination of methotrexate and its metabolite, 7-hydroxymethotrexate, although data from pharmacokinetic studies are inconsistent and conflicting. Displacement of methotrexate binding to serum albumin by certain NSAIDs may also play a secondary role. Unexpectedly severe and sometimes fatal bone marrow suppression, aplastic anemia, gastrointestinal toxicity, and nephrotoxicity have been reported during concomitant administration of methotrexate with NSAIDs. The risk is greatest in patients receiving high dosages of methotrexate and those with renal impairment.",
      "management_text": "NSAIDs should generally not be administered prior to or concomitantly with high dosages of methotrexate, such as those used to treat osteosarcoma. Caution should be exercised when NSAIDs are administered concomitantly with lower dosages of methotrexate. Close monitoring for signs and symptoms of bone marrow suppression, nephrotoxicity, and hepatotoxicity is recommended during treatment. Patients should be advised to contact their physician if they develop stomatitis, nausea, vomiting, diarrhea, rash, anorexia, jaundice, dark urine, dry cough, shortness of breath, and/or signs and symptoms of myelosuppression such as pallor, dizziness, fatigue, lethargy, fainting, easy bruising or bleeding, fever, chills, sore throat, body aches, and other influenza-like symptoms. Patients should also be counseled to avoid any other over-the-counter NSAID products.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106346,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Trimethoprim",
      "severity": "Major",
      "effect": "Coadministration of methotrexate with trimethoprim may increase the risk of severe myelosuppression and megaloblastic anemia due to potential additive effects resulting from inhibition of dihydrofolate reductase by both drugs. The interaction has been reported primarily with sulfamethoxazole-trimethoprim, but has also occurred with trimethoprim alone.",
      "management_text": "Concomitant use of methotrexate with trimethoprim should be avoided if possible. Some clinicians consider the use of methotrexate with low-dose sulfamethoxazole-trimethoprim (e.g., for the prophylaxis of Pneumocystis jiroveci pneumonia) to be acceptable; however, close monitoring for hematologic toxicity is recommended, particularly in the elderly. Complete blood counts, liver enzymes, and serum creatinine levels should be performed at baseline and periodically during treatment. Folate supplementation may be required in some cases. Patients should be advised to notify their doctor if they experience signs and symptoms of bone marrow depression or anemia such as fever, chills, sore throat, easy bruising or bleeding, pallor, dizziness, fatigue, lethargy, sore mouth or tongue, and tingling in hands or feet.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 106354,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Adefovir dipivoxil",
      "severity": "Major",
      "effect": "Coadministration of adefovir dipivoxil with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney.  Additionally, renal impairment secondary to the use of these agents may reduce the clearance of adefovir, which is primarily eliminated by renal excretion.  The use of adefovir dipivoxil has been associated with dose-related nephrotoxicity characterized by a delayed onset of gradual increases in serum creatinine and decreases in serum phosphorus.  Generally, the risk is low in patients with adequate renal function receiving 10 mg/day but increases with increasing dosage and in patients with underlying renal impairment.",
      "management_text": "Caution is advised if adefovir dipivoxil must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; cidofovir; tenofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; mesalamine; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents).  Renal function should be evaluated prior to and during therapy with adefovir dipivoxil.  Patients with renal insufficiency at baseline or during treatment may require dosage adjustment in accordance with the manufacturer's product labeling.",
      "mechanism_text": null,
      "risk_level": "Major",
      "source": "DDInter",
      "ddinter_id": 241015,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Abemaciclib",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 1196,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Abiraterone",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 1487,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Isotretinoin",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 2125,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Clostridium tetani toxoid antigen (formaldehyde inactivated)",
      "severity": "Moderate",
      "effect": "The administration of inactivated, killed, or otherwise noninfectious vaccines to immunosuppressed patients is generally safe but may be associated with a diminished or suboptimal immunologic response due to antibody inhibition. Such patients may include those who have recently received or are receiving immunosuppressive agents, antilymphocyte globulins, alkylating agents, antimetabolites, radiation, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents, or long-term topical or inhaled corticosteroids.",
      "management_text": "In general, the US Department of Public Health Advisory Committee on Immunization Practices (ACIP) recommends that inactivated or killed vaccines be administered to non-HIV immunosuppressed patients according to the same guidelines as for healthy patients. For Haemophilus influenzae b vaccine, some experts recommend that it be administered at least 2 weeks before starting or 3 months after discontinuing chemotherapy when used in patients with Hodgkin's disease. For rabies vaccine, some authorities suggest that immunosuppressive agents should generally be avoided during postexposure therapy except when absolutely necessary for the treatment of other conditions.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 8518,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Trastuzumab emtansine",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 9867,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Afatinib",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 10585,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Hydrocortisone",
      "severity": "Moderate",
      "effect": "Although they are often used together in clinical practice, limited data suggest that corticosteroids may increase the risk of methotrexate toxicity. Individual cases of severe and fatal bone marrow suppression and fatal systemic moniliasis have been reported.",
      "management_text": "Close monitoring for signs and symptoms of bone marrow suppression and nephrotoxicity is advisable during concomitant administration. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 11314,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Ethanol",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 12676,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Alectinib",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 13344,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Hydrochlorothiazide",
      "severity": "Moderate",
      "effect": "Antineoplastic-induced bone marrow suppression may be prolonged with concomitant thiazide administration. The mechanism is unknown. Thiazides have been associated with blood dyscrasias.",
      "management_text": "Alternative antihypertensive therapy may be advisable. Hematological status should be closely monitored in patients receiving this combination.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 17182,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Pioglitazone",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18352,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Alpelisib",
      "severity": "Moderate",
      "effect": "Coadministration with alpelisib may theoretically increase the plasma concentrations of drugs that are substrates of organic anion transporter (OAT3), intestinal breast cancer resistance protein (BCRP), and/or P-glycoprotein (P-gp). The proposed mechanism is decreased clearance due to inhibition of the corresponding transporter by alpelisib and/or its metabolite (BZG791).",
      "management_text": "Caution is advised if alpelisib must be used concomitantly with drugs that are substrates of the affected transporters, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever alpelisib is added to or withdrawn from therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 18911,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Amphotericin B",
      "severity": "Moderate",
      "effect": "The concurrent or sequential use of two or more potentially nephrotoxic or neurotoxic drugs may increase the risk of toxicity. Patients who are elderly, debilitated, dehydrated, or who have preexisting renal dysfunction may have a higher risk of developing adverse reactions.",
      "management_text": "Close clinical and laboratory monitoring of renal and neurologic function and drug serum concentrations (if clinically appropriate) is recommended.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20321,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Ambrisentan",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 20443,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Amiodarone",
      "severity": "Moderate",
      "effect": "A case report has suggested that amiodarone may increase the risk of methotrexate toxicity (particularly skin necrosis). The mechanism is unknown and causality could not be definitely determined.",
      "management_text": "Patients receiving this combination should be monitored for signs of dermatologic reactions (e.g., ulceration, necrosis).",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 21640,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Testosterone",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 25559,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Fenofibrate",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 26674,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Bupropion",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 28378,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Triamcinolone",
      "severity": "Moderate",
      "effect": "Although they are often used together in clinical practice, limited data suggest that corticosteroids may increase the risk of methotrexate toxicity. Individual cases of severe and fatal bone marrow suppression and fatal systemic moniliasis have been reported.",
      "management_text": "Close monitoring for signs and symptoms of bone marrow suppression and nephrotoxicity is advisable during concomitant administration. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 31019,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Asparaginase Erwinia chrysanthemi",
      "severity": "Moderate",
      "effect": "Nonclinical data suggest that the concomitant use of L-asparaginase and methotrexate may reduce the antineoplastic effect of methotrexate. The mechanism and clinical significance are unknown.",
      "management_text": "It is recommended to avoid concomitant or sequential use while plasma asparagine levels are below normal.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 33639,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Atorvastatin",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35852,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Atovaquone",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 35962,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Axitinib",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 36915,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Phenazopyridine",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38001,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Balsalazide",
      "severity": "Moderate",
      "effect": "Coadministration of 5-aminosalicylate with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of 5-aminosalicylate or its prodrugs has been associated with rare reports of renal impairment including minimal change nephropathy, acute and chronic interstitial nephritis, and renal failure.",
      "management_text": "Caution is advised when 5-aminosalicylate preparations are prescribed to patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides; polypeptide, glycopeptide, and polymyxin antibiotics; amphotericin B; adefovir; cidofovir; foscarnet; cisplatin; deferasirox; gallium nitrate; lithium; certain immunosuppressants; intravenous bisphosphonates; intravenous pentamidine; high intravenous dosages of methotrexate; high dosages and/or chronic use of nonsteroidal anti-inflammatory agents). Renal function should be evaluated prior to and during 5-aminosalicylate therapy.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 38609,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Dexamethasone",
      "severity": "Moderate",
      "effect": "Although they are often used together in clinical practice, limited data suggest that corticosteroids may increase the risk of methotrexate toxicity. Individual cases of severe and fatal bone marrow suppression and fatal systemic moniliasis have been reported.",
      "management_text": "Close monitoring for signs and symptoms of bone marrow suppression and nephrotoxicity is advisable during concomitant administration. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 39301,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Bempedoic acid",
      "severity": "Moderate",
      "effect": "Coadministration with bempedoic acid may increase the plasma concentrations and the risk of adverse effects of drugs that are substrates of the uptake transporters organic anion transporting polypeptide (OATP) 1B1 and 1B3. The proposed mechanism, based on in vitro data, is decreased clearance due to bempedoic acid-mediated inhibition of OATP1B1 and 1B3.",
      "management_text": "Caution is advised if bempedoic acid is used concomitantly with drugs that are substrates of OATP1B1 or 1B3, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever bempedoic acid is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40469,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Bendamustine",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 40707,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Bicalutamide",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 43562,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Binimetinib",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 43943,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Tetracycline",
      "severity": "Moderate",
      "effect": "Concomitant use of tetracyclines may elevate or reduce serum methotrexate concentrations. One mechanism may involve displacement of methotrexate from its binding to plasma proteins. Individual cases of methotrexate toxicity have been reported with doxycycline and tetracycline. In contrast, it has also been reported that oral antibiotics such as tetracyclines may reduce the intestinal absorption of methotrexate or interfere with its enterohepatic circulation or by inhibiting bowel flora and suppressing the metabolism of methotrexate by bacteria. However, the clinical significance of this effect has not been established.",
      "management_text": "If these drugs must be used together, close monitoring for evidence of serious methotrexate toxicity or reduced therapeutic efficacy is recommended. If broad-spectrum antibiotic coverage is needed during high-dose methotrexate therapy, the use of an alternate anti-infective may be considered.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 44780,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Blinatumomab",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45542,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Ibandronate",
      "severity": "Moderate",
      "effect": "Coadministration of bisphosphonates with other nephrotoxic agents may increase the risk and severity of renal impairment due to additive effects on the kidney. The use of bisphosphonates has been associated with nephrotoxicity manifested as deterioration of renal function and renal failure.",
      "management_text": "Caution is advised if pamidronate, zoledronic acid, or other intravenous formulations of bisphosphonates must be used in patients who have recently received or are receiving treatment with other potentially nephrotoxic agents (e.g., aminoglycosides, polypeptide and polymyxin antibiotics, vancomycin, amphotericin B, adefovir, cidofovir, tenofovir, foscarnet, cisplatin, gallium nitrate, lithium, mesalamine, certain immunosuppressants, intravenous pentamidine, high intravenous dosages of methotrexate, high dosages of nonsteroidal anti-inflammatory agents). Renal function and serum electrolytes should be monitored. Patients should have serum creatinine assessed prior to each treatment, and treatment should be withheld for renal deterioration.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 45822,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Bosutinib",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 46666,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Brentuximab vedotin",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 47125,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Brigatinib",
      "severity": "Moderate",
      "effect": "Coadministration with brigatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp), breast cancer resistance protein (BCRP), organic cation transporter 1 (OCT1), and/or multidrug and toxin extrusion protein 1 (MATE1), and 2K (MATE2K). The proposed mechanism, based on in vitro data, is decreased drug clearance due to brigatinib-mediated inhibition of these transport proteins.",
      "management_text": "Caution is advised if brigatinib is used concomitantly with drugs that are substrates of P-gp, BCRP, OCT 1, MATE 1, and/or MATE 2K transport proteins, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring should be considered whenever brigatinib is added to or withdrawn from therapy with these drugs. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 48203,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Budesonide",
      "severity": "Moderate",
      "effect": "Although they are often used together in clinical practice, limited data suggest that corticosteroids may increase the risk of methotrexate toxicity. Individual cases of severe and fatal bone marrow suppression and fatal systemic moniliasis have been reported.",
      "management_text": "Close monitoring for signs and symptoms of bone marrow suppression and nephrotoxicity is advisable during concomitant administration. Patients should be advised to report possible symptoms of toxicity including nausea, vomiting, diarrhea, stomatitis, sore throat, chills, fever, rash, unusual bruising or bleeding, jaundice, dark urine, swelling of the extremities, or shortness of breath to their physician.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 50182,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Busulfan",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 51911,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Calaspargase pegol",
      "severity": "Moderate",
      "effect": "Concomitant use of asparaginase with other hepatotoxic agents may potentiate the risk of liver injury. Hepatomegaly, acute severe hepatotoxicity, and fatal liver failure have been reported with asparaginase treatment in adults. Also, asparaginase may increase the toxicity of drugs bound to plasma proteins or metabolized by the liver.",
      "management_text": "The risk of additive hepatotoxicity should be considered when asparaginase is used with other hepatotoxic agents (e.g., alcohol, androgens, antituberculosis agents, azole antifungal agents, ACE inhibitors, macrolide antibiotics, nonsteroidal anti-inflammatory agents, nucleoside reverse transcriptase inhibitors, sulfonamides, thiazolidinediones, and statins). Liver function tests should be monitored at regular intervals during asparaginase treatment with or without other hepatotoxic drugs. Patients should be advised to seek medical attention if they experience potential symptoms of hepatotoxicity such as right upper quadrant pain, increasing abdominal size, fever, rash, itching, anorexia, nausea, vomiting, fatigue, malaise, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 53518,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Canakinumab",
      "severity": "Moderate",
      "effect": "The use of interleukin-1 blockers with other immunosuppressive or myelosuppressive agents may increase the risk of infections. Interleukin-1 blockade alone may cause neutropenia and serious infections, and the risk may be increased in the presence of other immunosuppressive therapy. Agents that may be significantly myelo- or immunosuppressive include antineoplastic agents, radiation, zidovudine, linezolid, some antirheumatic agents, high dosages of corticosteroids or adrenocorticotropic agents , and long-term topical or inhaled corticosteroids.",
      "management_text": "The safety and efficacy of interleukin-1 blockers in immunosuppressed patients have not been established. Until more information is available, interleukin-1 blockers should preferably not be administered to immunosuppressed patients, or they should be prescribed with extreme caution.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 54605,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Cannabidiol",
      "severity": "Moderate",
      "effect": "Coadministration of cannabidiol with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Cannabidiol causes dose-related elevations of liver transaminases, both alanine aminotransferase (ALT) and aspartate aminotransferase (AST).",
      "management_text": "Caution is advised if cannabidiol is used in patients who are currently receiving or have recently received treatment with other hepatotoxic agents, and vice versa. Serum transaminases and total bilirubin levels should be obtained prior to initiating cannabidiol, and patients with elevated baseline transaminase levels above 3 times the ULN accompanied by elevations in bilirubin above 2 times the ULN should be evaluated. Patients who develop clinical signs or symptoms suggestive of hepatic dysfunction (e.g., unexplained nausea, vomiting, right upper quadrant abdominal pain, fatigue, anorexia, jaundice, dark urine) should have serum transaminases and total bilirubin measured promptly, and cannabidiol treatment interrupted or discontinued as appropriate. Cannabidiol should be discontinued in patients with elevations of transaminase levels greater than 3 times the ULN and bilirubin levels greater than 2 times the ULN. Patients with sustained transaminase elevations of greater than 5 times the ULN should also have treatment discontinued. Patients with prolonged elevations of serum transaminases should be evaluated for other possible causes. Also consider dosage adjustment or discontinuation of any coadministered medication that is known to affect the liver.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 55047,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Capmatinib",
      "severity": "Moderate",
      "effect": "Coadministration with capmatinib may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance protein (BCRP) transporters, such as digoxin and rosuvastatin. The proposed mechanism is decreased clearance due to capmatinib-mediated inhibition of intestinal P-gp and/or BCRP efflux transport proteins.",
      "management_text": "Coadministration of capmatinib with drugs that are substrates of P-gp and/or BCRP should generally be avoided. However, if concomitant use is unavoidable, caution is advised, particularly with drugs that have a narrow therapeutic range. Clinical and laboratory monitoring should be considered whenever capmatinib is added to or withdrawn from therapy with these drugs, and dosages adjusted as necessary. Patients should be monitored for the development of adverse effects.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 55627,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Captopril",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 55979,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Carbamazepine",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 56469,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Carboplatin",
      "severity": "Moderate",
      "effect": "The concomitant or sequential administration of multiple antineoplastic agents may result in additive toxicities, particularly in the bone marrow and gastrointestinal tract.",
      "management_text": "Close clinical and laboratory monitoring for hematologic and nonhematologic toxicities are recommended when antineoplastic agents are administered concurrently or during close intervals. Dosing adjustments may be necessary. The manufacturers' recommendations and institutional protocols for dosage, treatment regimens, monitoring, and management of toxicities should be consulted.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 57557,
      "ingredient1": "Methotrexate"
    },
    {
      "ingredient2": "Carfilzomib",
      "severity": "Moderate",
      "effect": "Coadministration of methotrexate with other agents known to induce hepatotoxicity may potentiate the risk of liver injury. Methotrexate, especially at higher doses or with prolonged treatment, has been associated with hepatotoxicity including acute hepatitis, chronic fibrosis, necrosis, cirrhosis, and liver enzyme elevations.",
      "management_text": "The risk of hepatic injury should be considered when methotrexate is used with other potentially hepatotoxic agents (e.g., acetaminophen; alcohol; androgens and anabolic steroids; antituberculous agents; azole antifungal agents; ACE inhibitors; cyclosporine (high dosages); disulfiram; endothelin receptor antagonists; interferons; ketolide and macrolide antibiotics; kinase inhibitors; minocycline; nonsteroidal anti-inflammatory agents; nucleoside reverse transcriptase inhibitors; proteasome inhibitors; retinoids; sulfonamides; tamoxifen; thiazolidinediones; tolvaptan; vincristine; zileuton; anticonvulsants such as carbamazepine, hydantoins, felbamate, and valproic acid; lipid-lowering medications such as fenofibrate, lomitapide, mipomersen, niacin, and statins; herbals and nutritional supplements such as black cohosh, chaparral, comfrey, DHEA, kava, pennyroyal oil, and red yeast rice). Baseline and periodic monitoring of hepatic function is recommended, while liver biopsy may be warranted during long-term use of methotrexate. Patients should be advised to seek medical attention if they experience potential signs and symptoms of hepatotoxicity such as fever, rash, itching, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, pale stools, and jaundice.",
      "mechanism_text": null,
      "risk_level": "Moderate",
      "source": "DDInter",
      "ddinter_id": 58286,
      "ingredient1": "Methotrexate"
    }
  ]
}